GS 7/7/2017 1 sgourosCV_2017_07_07

_______________________ _July 7, 2017

George Sgouros, Ph.D. [Date of this version]

CURRICULUM VITAE

Table of Contents Current Primary Appointment ......................................... 2

Current Secondary Appointments ..................................... 2

Biographical ....................................................... 2

Education ......................................................... 2

Postdoctoral Training ................................................ 3

Positions and Appointments .......................................... 3

Publications ....................................................... 4

A. Peer-reviewed original research articles ............................ 4

B. Books and Other Monographs .................................... 16

Books ........................................................ 16

Chapters/Review Articles ........................................ 17

C. Other ....................................................... 20

Conference Proceedings ......................................... 20

Editorial/Commentary ........................................... 21

Media/interviews ............................................... 22

Patents and Software Copyrights ..................................... 23

Research Support (PI or Co-PI) ...................................... 24

Active ......................................................... 24

Pending ........................................................ 27

Previous ....................................................... 27

Clinical Trials ..................................................... 30

Teaching ......................................................... 32

Mentoring ........................................................ 33

Ph.D. Thesis committees ............................................ 36

Editorial Activities ................................................. 36

Scientific and Medical Societies ...................................... 37

Committees/Review Panels .......................................... 37

Honors & Awards .................................................. 38

Invited Talks, Panels ............................................... 39

GS 7/7/2017 2 sgourosCV_2017_07_07

_______________________ _July 14, 2016

George Sgouros, Ph.D. [Date of this version]

CURRICULUM VITAE

Current Primary Appointment

Johns Hopkins University, Professor of Radiology and Radiological Science,

School of Medicine, Director, Radiopharmaceutical Therapy Section,

Baltimore MD 21205 Division of Nuclear Medicine, Dept. of Radiology

2007-

Current Secondary Appointments

Johns Hopkins University, Professor of Radiation Oncology,

School of Medicine,

Baltimore MD 21205 2008-

Johns Hopkins University, Professor of Oncology,

School of Medicine,

Baltimore MD 21205 2009-

Biographical

Name George Sgouros

Date of birth March 31, 1963

Place of birth Munich, Germany

Citizenship United States

Office Address 4M61 CRB II Tel. #: 410 614 0116

1550 Orleans St E-mail: gsgouros@jhmi.edu

Johns Hopkins University, SOM Fax #: 413 487-3753

Baltimore MD 21231

Foreign Languages:Spoken - Greek

Education

Columbia University, B.S. (Applied Physics)

School of Engineering & Applied Science 1980-1984

New York, New York

Cornell University, Ph.D.

Graduate School of Medical Sciences, (Physiology & Biophysics)

New York, New York 1986-1991

GS 7/7/2017 3 sgourosCV_2017_07_07

Postdoctoral Training

Sloan-Kettering Institute Post-doctoral Research Fellow

Memorial Sloan-Kettering Cancer Center (Medical Physics)

New York, New York 1991-1993

Positions and Appointments

Memorial Sloan-Kettering Cancer Center Assistant/Associate Member (Medical Physics)

Memorial Hospital Assist./Assoc. Attending Physicist

New York, NY 10021 1993-1998/1998-2003

Cornell University Medical College Assistant/Associate Professor in Radiology

Cornell University (Radiology)

New York, NY 10021 1994-1999/1999-2003

Johns Hopkins University, Visiting Associate Professor (Radiology),

School of Medicine, Director, Radiopharm. Dosimetry Section,

Baltimore MD 21205 Division of Nuclear Medicine, Dept. of Radiology

2003-2005

Johns Hopkins University, Associate Professor (Radiology),

School of Medicine, Director, Radiopharm. Dosimetry Section,

Baltimore MD 21205 Division of Nuclear Medicine, Dept. of Radiology

2005-2007

GS 7/7/2017 4 sgourosCV_2017_07_07

Publications

A. Peer-reviewed original research articles

1. Bigler RE, Sgouros G. Biological analysis and dosimetry for 15

O-labeled O2, CO

2, and CO

gases administered continuously by inhalation. J Nucl Med 1983; 24(5):431-437.

2. Bigler RE, Zanzonico PB, Schmall B, Conti PS, Dahl JR, Rothman L, Sgouros G, MacEwen

EG. Evaluation of [1-11

C]-alpha-aminoisobutyric acid for tumor detection and amino acid

transport measurement: Spontaneous canine tumor studies. Eur J Nucl Med 1985; 10:48-55.

3. Sgouros G, Barest G, Thekkumthala J, Chui C, Mohan R, Bigler RE, Zanzonico PB.

Treatment planning for internal radionuclide therapy: Three-dimensional dosimetry for non-

uniformly distributed radionuclides. J Nucl Med 1990; 31(11):1884-1891.

4. Sgouros G. Plasmapheresis in radioimmunotherapy of micrometastases: A mathematical

modeling and dosimetrical analysis. J Nucl Med 1992; 33:2167-2179.

5. Sgouros G, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Modeling and dosimetry of

monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. J Nucl Med 1993;

34:422-430.

6. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations.

J Nucl Med 1993; 34:689-694.

7. Sgouros G, Chiu S, Pentlow KS, Brewster LJ, Kalaigian H, Baldwin B, Daghighian F,

Graham MC, Larson SM, Mohan R. Three-dimensional dosimetry for radioimmunotherapy

treatment planning. J Nucl Med 1993; 34:1595-1601.

8. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G,

Tyson D, Old LJ, Larson SM, Scheinberg DA. A phase 1B trial of humanized monoclonal

antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity.

Blood 1994; 83(7):1760-1768.

9. Lief EP, Sgouros G, Humm JL. General solution of the radioactive parent-daughter

relationship. Med Phys 1994; 21:1739-1740.

10. Scott AM, Macapinlac H, Zhang J, Kalaigian H, Graham MC, Divgi CR, Sgouros G,

Goldsmith SJ, Larson SM. Clinical applications of fusion imaging in oncology. Nucl Med

Biol 1994; 21:775-784.

11. Larson SM, Divgi CR, Scott A, Sgouros G, Graham MC, Kostakoglu L, Scheinberg D,

Cheung NV, Schlom J, Finn RD. Current status of radioimmunotherapy. Nucl Med Biol

1994; 21(5):785-792.

12. Scott AM, Macapinlac H, Divgi CR, Zhang J, Kalaigian H, Welt S, Pentlow K, Hilton S,

Graham MC, Sgouros G, Pelizzari C, Chen G, Schlom J, Goldsmith SJ, Larson SM. Clinical

GS 7/7/2017 5 sgourosCV_2017_07_07

validation of SPECT and CT/MRI registration in radiolabeled monoclonal antibody studies of

colorectal carcinoma. J Nucl Med 1994; 35:1976-1984.

13. Scott AM, Macapinlac H, Zhang J, Daghighian F, Montamayor N, Kalaigian H, Sgouros G,

Graham MC, Yeh SDJ, Lai E, Goldsmith SJ, Larson SM. Image registration of SPECT and

CT images using an external fiduciary band and 3-D surface fitting in a case of metastatic

thyroid cancer. J Nucl Med 1995; 36:100-103.

14. Willins J, Sgouros G. Modeling analysis of Platinum-195m for targeting individual blood-

borne cells in adjuvant radioimmunotherapy. J Nucl Med 1995; 36:315-319.

15. Ugur O, Scott AM, Kostakoglu L, Hui TE, Masterson ME, Febo R, Sgouros G, Rosa E, Mehta

B, Fisher DR, Cheung NV, Larson SM. Calculated and TLD-based absorbed dose estimates

for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse

model. Nucl Med Biol 1995; 22(1):87-93.

16. Nikula TK, Bocchia M, Curcio MJ, Sgouros G, Ma Y, Finn RD, Scheinberg DA. Impact of

the high tyrosine fraction in complementarity determining regions: Measured and predicted

effects of radioiodination on IgG immunoreactivity. Molecular Immunol 1995; 32:865-872.

17. Sgouros G, Jureidini IM, Scott AM, Graham MC, Larson SM, Scheinberg DA. Bone marrow

dosimetry: Regional variability of marrow-localizing antibody. J Nucl Med 1996; 37:695-698.

18. Furhang EE, Sgouros G, Chui C-S. Radionuclide photon dose kernels for internal emitter

dosimetry. Med Phys 1996; 23:759-764.

19. Furhang EE, Chui C-S, Sgouros G. A Monte Carlo approach to patient-specific dosimetry.

Med Phys 1996, 23:1523-1529.

20. Kolbert KS, Sgouros G, Scott AM, Bronstein JE, Malane RA, Zhang J, Kalaigian H,

McNamara S, Schwartz L, Larson SM. Implementation and evaluation of patient-specific

three-dimensional internal dosimetry. J Nucl Med 1997; 38:301-308.

21. Furhang EE, Chui C-S, Kolbert KS, Larson SM, Sgouros G. Implementation of a Monte

Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys 1997,

24:1163-1172.

22. Loh A, Sgouros G, O'Donoghue JA, Deland D, Puri D, Capitelli P, Humm JL, Larson SM,

Old LJ, Divgi CR. A pharmacokinetic model of 131I-G250 antibody in patients with renal cell

carcinoma. J Nucl Med 1998; 39:484-489.

23. Slovin SF, Scher HI, Divgi CR, Reuter V, Sgouros G, Moore M, Weingard K, Pettengall R,

Imbriaco M, El-Shirbiny A, Finn R, Bronstein J, Brett C, Milenic D, Dnistrian A, Shapiro L,

Schlom J, and Larson SM. Interferon- and monoclonal antibody 131I-labeled CC49:

outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 1998; 4:643-

651.

GS 7/7/2017 6 sgourosCV_2017_07_07

24. Behr TM, Sgouros G, Vougiokas V, Memtsoudis S, Gratz S, Schmidberger H, Blumenthal

RD, Goldenberg DM, Becker W. Therapeutic efficacy and dose-limiting toxicity of Auger-

electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of

125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer

1998;76:738-748.

25. Sgouros G. Yttrium-90 biodistribution by yttrium-87 imaging: A feasibility analysis. Med.

Phys. 1998; 25:1487-1490.

26. Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. Positron

emission tomography of a human prostate cancer xenograft: Association of changes in

deoxyglucose accumulation with other measures of outcome following androgen withdrawal.

Cancer Res, 1998; 58:3009-3014.

27. Sgouros G, O'Donoghue JA, Larson SM, Macapinlac H, Larson JJ, Kemeny N. Mathematical

model of 5-[125I]iodo-2'-deoxyuridine treatment: Continuous infusion regimens for hepatic

metastases. Int J Radiat Biol Oncol Phys 1998; 41:1177-1183.

28. Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F,

Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson

SM, Old LJ. Phase I/II radioimmunotherapy trial with iodine-131 labeled monoclonal

antibody (Mab) G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4:2729-2739.

29. McDevitt MR, Finn RD, Sgouros G, Ma D, Scheinberg DA. An 225Ac/213Bi generator system

for therapeutic clinical applications: construction and operation. Appl. Radiat. Isotopes 1999;

50:895-904.

30. Griffiths GL, Govindan SV, Sgouros G, Ong GL, Goldenberg DM, Mattes MJ. Cytotxicity

with Auger electron-emitting radionuclides delivered by antibodies. Int J Cancer 1999;

81:985-992.

31. Sgouros G, Ballangrud ÅM, Humm JL, Jurcic JG, McDevitt MR, Erdi YE, Mehta BM, Finn

RD, Geerlings MW, Larson SM, Scheinberg DA. Pharmacokinetics and dosimetry of an

alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

J Nucl Med, 1999; 40:1935-1946.

32. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of

patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med

1999; 40:2102-2106.

33. Ballangrud ÅM, Yang W-H, Dnistrian A, Lampen NM, Sgouros G. Growth and

characterization of LNCaP prostate cancer cell spheroids. Clin Cancer Res 1999; 5:3171s-

3176s.

34. Behr TM, Sgouros G, Stabin MG, Behe M, Angerstein C, Blumenthal RD, Apostolidis C,

Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W. Studies on the red marrow

dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the

radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-

emitters. Clin Cancer Res. 1999 Oct;5(10 Suppl):3031s-3043s

GS 7/7/2017 7 sgourosCV_2017_07_07

35. Hamacher KH, Sgouros G. A schema for estimating absorbed dose to organs following the

administration of radionuclides with multiple unstable daughters: A matrix approach. Med

Phys 1999; 26:2526-2528

36. O’Donoghue JA, Sgouros G, Divgi CR, Humm JL. Single dose versus fractionated

radioimmunotherapy: Model comparisons for uniform tumor dosimetry. J Nucl Med 2000;

41:538-547.

37. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H,

Rosai J, Robbins RJ. Prognostic value of FDG-PET scanning in patients with thyroid cancer. J

Clin Endocrinol Metab 2000; 85:1107-1113.

38. Sgouros G, Stabin M, Erdi Y, Akabani G, Kwok C, Brill AB, Wessels B. Red marrow

dosimetry for radiolabeled antibodies that bind to marrow, bone or blood components. Med

Phys 2000; 27:2150-2164.

39. Behr TM, Behe M, Lohr M, Sgouros G, Angerstein C, Wehrmann E, Nebendahl K, Becker W.

Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when

conjugated to internalizing antibodies. Eur J Nuc Med 2000; 27:753-765.

40. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang

W, Finn RD, Pellegrini V, Geerlings MW, Jr., Lee M, Brechbiel MW, Bander NH, Cordon-

Cardo C, Scheinberg DA. An alpha-particle emitting antibody (J591) for radioimmunotherapy

of prostate cancer. Cancer Res 2000; 60:6095-6100.

41. Govindan SV, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, Brechbiel MW, Burton J,

Sgouros G, Mattes MJ. Radionuclides linked to CD74 antibody as therapeutic agents for B-

cell lymphoma: Comparison of Auger electron emitters with -particle emitters. J Nucl Med

2000; 41:2089-2097.

42. Kolbert KS, Hamacher KA, Jurcic JG, Scheinberg DA, Larson SM, Sgouros G. Parametric

images of antibody pharmacokinetics in Bi-213-HuM195 Therapy of Leukemia. J Nucl Med

2001; 42:27-32.

43. Hamacher KA, Den RB, Den EI, Sgouros G. Cellular dose conversion factors for alpha-

particle emitting radionuclides of interest in radionuclide therapy. J Nucl Med 2001; 42:1216-

1221.

44. Emfietzoglou D, Kostarelos K, Sgouros G. An analytical dosimetry study for the use of

radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 2001; 42:499-504.

45. Barendswaard EC, Welt S, Humm JL, O'Donoghue JA, Sgouros G, Finn RD, Scott AM,

Larson SM, Old LJ. Relative therapeutic efficacy of I-125 and I-131 labeled monoclonal

antibody A33 in a human colon cancer xenograft. J Nucl Med 2001; 42:1251-1256.

46. Ballangrud AM, Yang W, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D,

Bander NH, Scheinberg DA, Sgouros G. Response of LNCaP spheroids following treatment

GS 7/7/2017 8 sgourosCV_2017_07_07

with alpha-particle emitter (213Bi)-labeled anti-PSMA antibody (J591). Cancer Res 2001;

61:2008-2014.

47. Thomas SR, Watson EE, Bolch WE, Brill AB, Charkes ND, Fisher DR, Hays MT, Howell

RW, Meredith RF, Robertson JS, Sgouros G, Siegel JA, Wessels BW. MIRD Pamphlet No.

18: Administered cumulated activity for ventilation studies. J Nucl Med 2001; 42:520-526.

48. Hamacher KA, Sgouros G. Theoretical estimation of absorbed dose to organs in

radioimmunotherapy using radionuclides with multiple unstable daughters. Med Phys 2001;

28:1857-1874.

49. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm

JL, DeNardo SJ. Rationales, evidence, and design considerations for fractionated

radioimmunotherapy. Cancer 2002; 94(4 Suppl):1332-48.

50. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud ÅM,

Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted

particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-1239.

51. O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. Hematologic toxicity in

radioimmunotherapy: Dose-response relationships in I-131 labeled antibody therapy. Cancer

Biother Radiopharm 2002; 17:435-443.

52. Behr RM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with

myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of

radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer

Biother Radiopharm 2002; 17:445-464.

53. Sgouros G, Squeri S, Ballangrud ÅM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, Divgi

CR, Larson SM, Zelenetz AD. Patient-Specific, 3-D dosimetry in Non-Hodgkin’s Lymphoma

Patients Treated with 131I-anti-B1 Antibody: Assessment of tumor dose-response. J Nucl Med

2003; 44:260-268.

54. Kolbert KS, Watson T, Matei C, Xu S, Koutcher JA, Sgouros G. Murine S-factors for Liver,

Spleen and Kidney. J Nucl Med 2003; 44 784-791

55. Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA, Clairand I, Sgouros

G. MIRD pamphlet no. 19: absorbed fractions and radionuclide S values for six age-dependent

multiregion models of the kidney. J Nucl Med. 2003; 44:1113-1147

56. Palm S, Enmon RM, Matei C, Kolbert KS, Xu S, Pellegrini V, Zanzonico PB, Finn RL,

Koutcher JA, Larson SM, Sgouros G. Pharmacokinetics and biodistribution of 86Y-

Trastuzumab for 90Y dosimetry in an ovarian carcinoma model: Correlative microPET and

MRI. J Nucl Med 2003; 44:1148-1155.

57. Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD,

Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG. Cytoreduction with iodine-131-anti-

GS 7/7/2017 9 sgourosCV_2017_07_07

CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone

Marrow Transplant 2003; 32:549-56.

58. Enmon R, Yang W, Ballangrud ÅM, Solit DB, Heller G, Rosen N, Scher HI, Sgouros G.

Combination treatment with 17AAG and acute irradiation produces supra-additive growth

suppression in human prostate carcinoma spheroids. Cancer Res 2003; 63: 8393-8399.

59. Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA.

Pharmacokinetics and toxicity of the targetable atomic generator, actinium-225-HuM195 in

non-human primates. J Nucl Med 2004; 45:129-37.

60. Sofou S, Thomas JL, Lin H, McDevitt MR, Scheinberg DA, Sgouros G. Engineered

liposomes for potential -particle therapy of metastatic cancer. J Nucl Med 2004; 45:253-260.

61. Ballangrud ÅM, Yang W-H, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR,

Scheinberg DA, Sgouros G. Alpha-particle emitting atomic generator (225Ac)-labeled

Trastuzumab (Herceptin) targeting of breast cancer spheroids: Efficacy versus HER2/neu

expression. Clin Cancer Res, 2004; 10:4489-97.

62. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, Larson SM.

Patient-specific dosimetry for 131I thyroid cancer therapy using 124I-PET and 3D-ID. J Nucl

Med, 2004; 45:1366-72.

63. Kostarelos K, Emfietzoglou D, Papakostas A, Yang W-H, Ballangrud ÅM, Sgouros G.

Binding and interstitital penetration of liposomes with avascular tumor spheroids. Int J

Cancer, 2004 Nov 20;112(4):713.

64. Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, Stabin MG,

Sgouros G. Bone marrow dosimetry using blood-based models for radiolabeled antibody

therapy: a multiinstitutional comparison. J Nucl Med 2004; 45:1725-33.

65. Emfietzoglou D, Kostarelos K, Papakostas A, Yang W-H, Ballangrud ÅM, Song H, Sgouros

G. Liposome mediated radiotherapeutics using avascular tumor spheroids: Comparative

dosimetry study for various radionuclides, liposome systems and a targeting antibody. J Nucl

Med 2005; 46:89-97.

66. Watchman CJ, Jokisch DW, Patton PW, Rajon DA, Sgouros G, Bolch WE. Absorbed

fractions for alpha particles in tissues of trabecular bone-considerations of marrow cellularity

within the ICRP reference male. J Nucl Med 2005; 47:1171-1185.

67. Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA.

Efforts to control the errant products of a targeted in vivo generator. Cancer Res; 2005;

65:4888-4895.

68. Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulo-

interstitial changes following internal irradiation with alpha-particle emitting actinium

daughters. J Amer Soc Nephrology 2005; 16(9):2677-89.

GS 7/7/2017 10 sgourosCV_2017_07_07

69. Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud AM, Sgouros G.

Enginering lipid vesicles of enhanced intratumoral transport capabilities: Correlating liposome

characteristics with penetration into human prostate tumor spheroids. J Liposome Res 2005;

15:15-27.

70. Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA. Mitigation of

radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol

Biol Physics 2006; 64:1503-12.

71. Sgouros G, Song H, Ladenson PW, Wahl RL. Lung toxicity in radioiodine therapy of thyroid

carcinoma: Development of a dose-rate method and dosimetric Implications of the 80 mCi

rule. J Nucl Med, 2006; 47:1977-1984 (PMC2974326).

72. Song H, He B, Prideaux AR, Du Y, Frey EC, Kasecamp W, Ladenson PW, Wahl RL,

Sgouros G. Lung dosimetry for radioiodine therapy treatment planning in the case of diffuse

lung metastases. J Nucl Med, 2006; 47:1985-1994.

73. Song H, Du Y, Sgouros G, Prideaux AR, Frey EC, Wahl RL. Therapeutic potential of 90Yttrium and 131Iodine-labeled anti-CD20 monoclonal antibody in treating Non-Hodgkin’s

lymphoma patients with pulmonary involvement: A Monte Carlo based dosimetric analysis. J

Nucl Med, 2007; 48:150-157.

74. Prideaux AR, Song H, Hobbs RF, He B, Frey EC, Ladenson PW, Wahl RL, Sgouros G. Three-

Dimensional Radiobiological Dosimetry (3D-RD): Application of radiobiological modeling to

patient-specific, 3-D imaging-based internal dosimetry. J Nucl Med, 2007; 48:1008-1016.

75. Petoussi-Henss N, Bolch WE, Zankl M, Sgouros G, Wessels B. Patient-specific scaling of

reference s-values for cross-organ radionuclide s-values: what is appropriate? Radiat Prot

Dosimetry. 2007;127(1-4):192-6

76. Singh Jaggi J, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J,

Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, Larson SM, Scheinberg DA.

Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of

neonatal Fc receptor. J Clin Invest. 2007 Sep 4;117(9):2422-2430.

77. Sofou S, Kappel BJ, Jaggi JS, McDevitt MR, Scheinberg DA, Sgouros G. Enhanced retention

of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers. Bioconjug

Chem 2007 Nov-Dec; 18(6):2061-7 (PMC2582153).

78. Sgouros G, Hong S. Cancer stem cell targeting using the alpha-particle emitter, 213Bi:

mathematical modeling and feasibility analysis. Cancer Biother Radipahrm. 2008 23:74-81

(PMC2977973).

79. Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological

effective dose to the MIRD schema and possible implications in radionuclide therapy

dosimetry. Med Phys. 2008 35:1123-1134 (PMC2974633).

80. Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ,

Sgouros G, Kozikowski AP, Pomper MG. N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-

GS 7/7/2017 11 sgourosCV_2017_07_07

[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin

Cancer Res. 2008;14(10):3036-43 (PMC3078104).

81. Zhao JM, Har-el Y, McMahon MT, Zhou J, Sherrry DA, Sgouros G, Bulte JWM, van Zijl

PCM. Size-induced enhancement of chemical exchange saturation transfer (CEST) contrast in

liposomes. J Am Chem Soc. 130 (15), 5178–5184, 2008 (PMC2759111).

82. Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S,

Sgouros G, Emens LA, Reilly RT, Jaffee EM. Antibody enhanced HER-2/neu targeted

vaccine induction of CD8+ T cell responses through the Fc-activation of dendritic cells. J Clin

Invest. 2008; 118(5):1700-11 (PMC2289797).

83. Song H, Shahverdi K, Huso DL, Esaias C, Fox J, Liedy A, Zhang Z, Reilly RT, Apostolidis C,

Morgenstern A, Sgouros G. 213Bi (alpha-emitter)-antibody targeting of breast cancer

metastases in the neu-N transgnic mouse model. Cancer Res. 2008; 68(10):3873-80

(PMC2981030).

84. He B, Wahl RL, Du Y, Sgouros G, Jacene H, Flinn I and Frey EC. Comparison of Residence

Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning -

Monte Carlo Simulation Studies. IEEE Trans. Med. Img. 2008; 27(4): 521-530

(PMC2588667).

85. Song H, Shahverdi K, Huso DL, Wang Y, Fox J, Hobbs RF, Gimi B, Gabrielson K, Pomper

MG, Tsui B, Bhujwalla Z, Reilly RT, Sgouros G. An immunotolerant HER-2/neu transgenic

mouse model of metastatic breast cancer. Clin Cancer Res. 2008; 14(19):6116-25

(PMC2570093).

86. Fu D, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong J, Hobbs RF, Fukayama M, Sgouros G,

Kowalski J, Pomper MG, Ambinder RF. Bortezomib-induced enzyme-targeted radiotherapy in

herpes virus-associated tumors. Nat Med 2008;14(10):1118-22 (PMC2709824).

87. Baechler S, Hobbs RF, Prideaux AR, Recordon M, Bischof-Delaloye A, Sgouros G.

Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab

tiuxetan. Cancer Biother Radiopharm 2008; 23(5):633-9 (PMC2936951).

88. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, Green AJ,

Bouchet LG, Brill AB, Bolch WE, Sgouros G, Thomas SR. MIRD pamphlet No. 20: the

effect of model assumptions on kidney dosimetry and response--implications for radionuclide

therapy. J Nucl Med 2008; 49(11):1884-99

89. He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, Frey EC. Evaluation of quantitative

imaging methods for organ activity and residence time estimation using a population of

phantoms having realistic variations in anatomy and uptake. Med Phys 2009; 36(2):612-619

(PMC2848525).

90. Hobbs RF, Sgouros G. Calculation of the biological effective dose for piecewise defined dose-

rate fits. Med Phys. 2009 Mar;36(3):904-7 (PMC2736747).

GS 7/7/2017 12 sgourosCV_2017_07_07

91. Loeb DM, Garrett-Mayer E, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Wharam MD Jr,

Scott T, Schwartz CL. Dose-finding study of (153)Sm-EDTMP in patients with poor-prognosis

osteosarcoma. Cancer. 2009 115(11):2514-22 (PMC2974628).

92. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: A

Generalized Schema for Radiopharmaceutical Dosimetry--Standardization of

Nomenclature. J Nucl Med 2009; 50(3):477-484 .

93. He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR, Flinn I, Hammes RJ, Bianco

J, Kahl B, Frey EC. Comparison of organ residence time estimation methods for

radioimmunotherapy dosimetry and treatment planning – patient studies. Med Phys 2009;

36:1595-1601 (PMC2851232).

94. Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, Ewertz ME, Esaias CE,

Ladenson PW, Sgouros G. 124I PET-based 3D-RD dosimetry for a pediatric thyroid

cancer patient: Real-time treatment planning and methodological comparison. J Nucl Med,

2009; 50(11):1844-1847 (PMC2844448).

95. Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, Morgenstern A,

Sgouros G. Radioimmunotherapy of breast cancer metastases with alpha-particle-emitter 225Ac: Comparing efficacy with 213Bi, 90Y. Cancer Res, 2009;69(23):8941-8

(PMC2789180).

96. Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre-therapeutic 124I PET/CT

dosimetry confirms low average absorbed doses per administered 131I activity to the salivary

glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging

2010 May;37(5):884-95 (PMC2854857).

97. Sofou S, Enmon R, Palm S, Kappel B, Zanzonico P, McDevitt MR, Scheinberg DA, Sgouros

G. Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of

micrometastatic cancer. J Liposome Res. 2010 Dec;20(4):330-40 (PMC3172685).

98. Hobbs RF, Baechler S, Senthamizhchelvan S, Prideaux AR, Esaias CE, Reinhardt M, Frey EC,

Loeb DM, Sgouros G. Camera saturation in whole body planar imaging: An algorithmic

solution. Phys Med Biol. 2010 Feb 7;55(3):817-31 (PMC2844671).

99. Hobbs RF, Baechler S, Wahl RL, He B, Song H, Esaias CE, Frey EC, Jacene H, Sgouros G.

Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.

J Nucl Med, 2010 Mar;51(3):368-75 (PMC2967028).

100. Lingappa, M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G.

Immunoliposomal Delivery of 213Bi for α-Emitter Targeting of Metastatic Breast Cancer.

Cancer Res 2010 Sep 1;70(17):6815-23 (PMC2977986).

101. Loeb DM, Hobbs RF, Okoli A, Chen AR, Cho S, Srinivasan S, Sgouros G, Shokek O,

Wharam MD Jr, Scott T, Schwartz CL. Tandem dosing of samarium-153 ethylenediamine

tetramethylene phosphoric acid with stem cell support for patients with high-risk

osteosarcoma. Cancer. 2010 Dec 1;116(23):5470-8 (PMC2991401).

GS 7/7/2017 13 sgourosCV_2017_07_07

102. Dieudonné A, Hobbs RF, Bolch WE, Sgouros G, Gardin I. Fine-Resolution Voxel S Values

for Constructing Absorbed Dose Distributions at Variable Voxel Size. J Nucl Med. 2010

Oct;51(10):1600-7 (PMC2974318).

103. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney

ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential

Cytarabine and {alpha}-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for

Acute Myeloid Leukemia. Clin Cancer Res. 2010 Nov 1;16(21):5303-11 (PMC2970691).

104. Baechler S, Hobbs RF, Jacene HA, Bochud FO, Wahl RL, Sgouros G. Predicting hematologic

toxicity in patients undergoing radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I-

Tositumomab. J Nucl Med, 2010 Dec;51(12):1878-84 (PMC3169802).

105. Hobbs RF, McNutt T, Baechler S, He B, Esaias CE, Frey EC, Loeb DM, Wahl RL, Shokek O,

Sgouros G. A treatment planning method for sequentially combining radiopharmaceutical

therapy (RPT) with external radiation therapy (XRT). Int J Radiat Oncol Biol Phys, 2011

80:1256-62 (PMC3090537)

106. Senthamizhchelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J, Hobbs RF, Sgouros G,

Bengel FM Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med. 2011

Oct;51(10):1592-9 (PMC3172678).

107. Senthamizhchelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J, Hobbs RF, Bengel FM,

Sgouros G. Radiation dosimetry of 82Rb in humans under pharmacologic stress. J Nucl Med.

2011 Mar;52(3):485-91 (PMC3172687)

108. Hobbs RF, Baechler S, Fu DX, Esaias C, Pomper MG, Ambinder RF, Sgouros G. A model of

cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy. Med Phys 2011

Jun;38(6):2892-903 (PMC3117894).

109. Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros

G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-

Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging

Agent for Prostate Cancer. Clin Cancer Res 2011;17 7645-7653 (PMC3243762).

110. Sgouros G, Frey EC, Bolch WE, Wayson MB, Abadia AF, Treves ST. An approach for

balancing diagnostic image quality with cancer risk: application to pediatric diagnostic

imaging of 99mTc-dimercaptosuccinic acid. J Nucl Med. 2011; 52(12):1923-9

(PMC3290866).

111. Senthamizhchelvan S, Hobbs RF, Song H, Frey EC, Zhang Z, Armour E, Wahl RL, Loeb DM,

Sgouros G. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene

phosphonic acid therapy of high-risk osteosarcoma. J Nucl Med. 2012;53:215-24

(PMC3291096).

112. Wayson M, Lee C, Sgouros G, Treves ST, Frey E, Bolch WE. Internal photon and electron

dosimetry of the newborn patient--a hybrid computational phantom study. Phys Med Biol.

2012; 57:1433-57 (PMC pending).

GS 7/7/2017 14 sgourosCV_2017_07_07

113. Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD.

Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors

after depletion of effector/memory-like regulatory T cells. PLoS One. 2012;7:e31962

(PMC3281086).

114. Liu G, Moake M, Har-El YE, Long CM, Chan KW, Cardona A, Jamil M, Walczak P, Gilad

AA, Sgouros G, van Zijl PC, Bulte JW, McMahon MT. In vivo multicolor molecular MR

imaging using diamagnetic chemical exchange saturation transfer liposomes. Magn Reson

Med. 2012 67:1106–1113 (PMC3522097).

115. Cheng Y, Senthamizhchelvan S, Agarwal R, Green GM, Mease RC, Sgouros G, Huso DL,

Pomper MG, Meltzer SJ, Abraham JM. [( 32) P]ATP inhibits the growth of xenografted

tumors in nude mice. Cell Cycle 2012 11:1878-1882 (PMC3359117).

116. Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, Flux GD, Sgouros G.

A bone marrow toxicity model for (223)Ra alpha-emitter radiopharmaceutical therapy. Phys

Med Biol. 2012 57:3207-22 (PMC3442928).

117. Hobbs RF, Song H, Huso DL, Sundel M, Sgouros G. A nephron-based model of the kidneys

for macro-to-micro α-particle dosimetry. Phys Med Biol. 2012; 57:4403-24 (PMC3465844).

118. Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, Ljungberg M.

MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in

Internal Radionuclide Therapy. J Nucl Med. 2012; 53:1–16 (PMC3465844).

119. Baechler S, Hobbs RF, Boubaker A, Buchegger F, He B, Frey EC, Sgouros G. Three-

dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor

radionuclide therapy. Med Phys. 2012; 39:6118-6128 (PMC3465355).

120. Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres

CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C,

Slusher BS, Kozikowski AP, Pomper MG. Biodistribution, tumor detection, and radiation

dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane

antigen, in patients with metastatic prostate cancer.J Nucl Med. 2012 Dec;53(12):1883-91

(PMC3742115)

121. Dieudonné A, Hobbs RF, Lebtahi R, Maurel F, Baechler S, Wahl RL, Boubaker A, Le

Guludec D, Sgouros G, Gardin I. Study of the Impact of Tissue Density Heterogeneities on 3-

Dimensinal Abdominal Dosimetry: Comparison Between Dose Kernel Convolution and Direct

Monte Carlo Methods. J Nucl Med. 2013 Feb;54(2):236-43 (PMC4060982)

122. Hobbs RF, Jentzen W, Bockisch A, Sgouros G. Monte Carlo-based 3-dimensional dosimetry

of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using

124I PET. Q J Nucl Med Mol Imaging. 2013 Mar;57(1):79-91 (PMC4037814)

123. Cheng L, Hobbs RF, Segars PW, Sgouros G, Frey EC. Improved dose-volume histogram

estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction

parameters. Phys Med Biol. 2013 Jun 7;58(11):3631-47. (PMC4151254)

GS 7/7/2017 15 sgourosCV_2017_07_07

124. Hobbs RF, Wahl RL, Frey EC, Kasamon Y, Song H, Huang P, Jones RJ, Sgouros G.

Radiobiological optimization of combination radiopharmaceutical therapy applied to

myeloablative treatment of non-Hodgkin’s lymphoma. J Nucl Med 2013 54(9):1535-42.

(PMC4142210)

125. Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, DeWeese TL,

Sgouros G. Targeting Aberrant DNA double strand break repair in triple negative breast

cancer with alpha particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther. 2013

Oct;12(10):2043-54. (PMC3804319)

126. Botta F, Mariani A, Hobbs RF, Vergara Gil A, Pacilio M, Parodi K, Cremonesi M, Coca Pérez

MA, Di Dia A, Ferrari M, Guerriero F, Battistoni G, Pedroli G, Paganelli G, Torres Aroche

LA, Sgouros G. Use of the FLUKA monte carlo code for 3D patient-specific dosimetry on

PET-CT and SPECT-CT images. Phys Med Biol 2013 58(22):8099-120. (PMC4037810)

127. Hobbs RF, Howell RW, Song H, Baechler S, Sgouros G. Redefining relative biological

effectiveness in the context of the EQDX formalism: Implications for alpha-particle emitter

therapy. Rad Res 2014 Jan; 181(1):90-98. (PMC3984880)

128. Cheng L, Hobbs RF, Sgouros G, Frey EC. Development and evaluation of convergent and

accelerated penalized SPECT image reconstruction methods for improved dose-volume

histogram estimation in radiopharmaceutical therapy. Med Phys 2014 Nov; 41(11):2507

(PMC4241887)

129. Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Srinivasan S, Hobbs RF, Baidoo KE,

Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG. Preclinical Evaluation

of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates. J

Nucl Med. 2015 Apr;56(4):628-34

130. Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H,

Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper

MG. Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-

Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015 Apr 21. [Epub ahead of

print]

131. Kiess AP, Minn I, Chen Y, Hobbs R, Sgouros G, Mease RC, Pullambhatla M, Shen CJ, Foss

CA, Pomper MG. Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane

Antigen. J Nucl Med. 2015 Sep;56(9):1401-7. doi: 10.2967/jnumed.115.155929. Epub 2015

Jul 16.

132. Woliner-van der Weg W, Schoffelen R, Hobbs RF, Gotthardt M, Goldenberg DM, Sharkey

RM, Slump CH, van der Graaf WT, Oyen WJ, Boerman OC, Sgouros G, Visser EP. Tumor

and red bone marrow dosimetry: comparison of methods for prospective treatment planning in

pretargeted radioimmunotherapy. EJNMMI Phys. 2015 Dec;2(1):5. doi: 10.1186/s40658-014-

0104-x. Epub 2015 Feb 24.

133. Josefsson A, Nedrow JR, Park S, Banerjee SR, Rittenbach A, Jammes F, Tsui B, Sgouros G.

Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an

GS 7/7/2017 16 sgourosCV_2017_07_07

Immunocompetent Mouse Model of Breast Cancer. Cancer Res. 2015 Nov 10. [Epub ahead of

print]

134. Plyku D, Loeb DM, Prideaux AR, Baechler S, Wahl RL, Sgouros G, Hobbs RF. Strengths and

Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with

Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry. Cancer

Biother Radiopharm. 2015 Nov;30(9):369-79. doi: 10.1089/cbr.2014.1803

135. O’Reilly SE, Plyku D, Sgouros G, Fahey FH, Treves TS, Frey EC, Bolch WE. A risk index for

pediatric patients undergoing diagnostic imaging with (99m)Tc-dimercaptosuccinic acid that

accounts for body habitus. Phys Med Biol. 2016 Mar 21;61(6):2319-32. PMID: 26930549

136. Khamwan K, Plyku D, O'Reilly SE, Goodkind A, Cao X, Fahey FH, Treves ST, Bolch WE,

Sgouros G. Pharmacokinetic modeling of [(18)F]fluorodeoxyglucose (FDG) for premature

infants, and newborns through 5-year-olds. EJNMMI Res. 2016 Dec;6(1):28. PMID:

26988861

137. Yoshida T, Jin K, Song H, Park S, Huso DL, Zhang Z, Liangfeng H, Zhu C, Bruchertseifer F,

Morgenstern A, Sgouros G, Sukumar S.Effective treatment of ductal carcinoma in situ with a

HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast

cancer. Oncotarget. 2016 Apr 23. PMCID: PMC5078096

138. Kiess A, Minn IL, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, Brummet M, Chen Y,

Choi J, Koumarianou E, Baidoo K, Brechbiel M, Mease RC, Sgouros G, Zalutsky MR,

Pomper M. (2S)-2-(3-(1-Carboxy-5-(4-[211At]astatobenzamido)pentyl)ureido)-pentanedioic

acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy. J Nucl Med. 2016

Oct;57(10):1569-1575. PMID: 27230930

139. Chen Y, Lisok A, Chatterjee S, Wharram B, Pullambhatla M, Wang Y, Sgouros G, Mease RC,

Pomper MG. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid

Normal Organ Clearance. Bioconjug Chem. 2016 Jul 20;27(7):1655-62. PMID: 27270097

140. Plyku D, Hobbs RF, Huang K, Atkins F, Garcia C, Sgouros G, Van Nostrand D. Recombinant

Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-

Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer. J Nucl Med.

2017 Jul;58(7):1146-1154

141. Nedrow JR, Josefsson A, Park S, Ranka S, Roy S, Sgouros G. Imaging of programmed death

ligand-1 (PD-L1): Impact of protein concentration on distribution of anti-PD-L1 SPECT agent

in an immunocompetent melanoma murine model. J Nucl Med jnumed.117.193268 published

ahead of print May 18, 2017 (10.2967/jnumed.117.193268)

B. Books and Other Monographs

Books

1. Zaidi H, Sgouros G, Ed. Monte Carlo calculations in nuclear medicine: Therapeutic

applications. Institute of Physics Publishing, 2002.

GS 7/7/2017 17 sgourosCV_2017_07_07

2. Sgouros G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical

Therapy with Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging

Publishing, 2014

Chapters/Review Articles

1. Sgouros G, Scheinberg DA. The treatment of leukemia with radiolabeled monoclonal

antibodies. In: Steven T. Rosen, Timothy M. Kuzel , Editors. Immunoconjugate Therapy of

Hematologic Malignancies. Kluwer Academic Press, 23-64, 1993.

2. Sgouros G, Scheinberg DA. Treatment of leukemia with radiolabeled monoclonal antibodies.

Cancer Treat Res 1993;68:23-64

3. Larson SM, Sgouros G, Cheung NKV. Monoclonal Antibodies in Cancer Therapy:

Radioisotope conjugates. In: DeVita VT, Hellman S, Rosenberg SA, Editors. Biologic

Therapy of Cancer (2nd Edition), Lippincott, 534-552, 1995.

4. Junghans RP, Sgouros G, Scheinberg DA. Antibody-based Immunotherapies for Cancer. In:

Chabner B and Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles and

Practice, 2nd Edition, Lippincott, 655-689, 1996.

5. Larson SM, Sgouros G, Cheung NKV. Radiolabeled Antibodies: General Issues. In: Bertino

J, Ed. Encyclopedia of Cancer, Academic Press, 1407-1431, 1996.

6. Sgouros G. Radioimmunotherapy of Micrometastases. In: Riva P, Ed. Cancer

Radioimmunotherapy – Present and Future. Harwood Academic Publishers, 191-207, 1998.

7. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA.

Radioimmunotherapy with alpha-emitting nuclides. Eur J Nuc Med, 25:1341-1351, 1998.

8. Larson SM, Divgi C, Sgouros G, Cheung NV, Scheinberg DA. Principles and Practice of

Monoclonal Antibody Therapy:Radioisotope Conjugates. In:Rosenberg SA, Editor. Principles

and Practice of the Biologic Therapy of Cancer, 3rd Edition, Lippincott, 396-412, 2000.

9. Scheinberg DA, Sgouros G, Junghans RP,. Antibody-based Immunotherapies for Cancer. In:

Chabner B and Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles and

Practice, 3rd Edition, Lippincott, 850-860, 2001.

10. Sgouros G. Radiolabeled Antibodies: Overview. In: Bertino J, Ed. Encyclopedia of Cancer,

2nd Edition, Academic Press, 29-39, 2002.

11. Sgouros G, Yang W-H, Enmon R. Spheriods of Prostate Tumor Cell Lines. In: Jackson P,

Russell P, Eds. Prostate Cancer: Methods and Protocols, The Humana Press, Inc., 2003.

12. Manuel B, Kwok C, Sgouros G. Dose point-kernels for radionuclide dosimetry. In: Zaidi H,

Sgouros G, Ed. Monte Carlo calculations in nuclear medicine: Therapeutic applications.

Institute of Physics Publishing, 158-174, 2002.

GS 7/7/2017 18 sgourosCV_2017_07_07

13. Sgouros G, Kolbert KS. The three-dimensional internal dosimetry software package, 3D-ID.

In: Zaidi H, Sgouros G, Ed. Monte Carlo calculations in nuclear medicine: Therapeutic

applications. Institute of Physics Publishing, 249-261, 2002.

14. Ljungberg M, Dewarja Y, Sgouros G, Strand S. Evaluation and validation of dose calculation

procedures in patient-specific radionuclide therapy. In: Zaidi H, Sgouros G, Ed. Monte Carlo

calculations in nuclear medicine: Therapeutic applications. Institute of Physics Publishing,

262-285, 2002.

15. Sgouros G. Dosimetric and radiobiological considerations: Patient-specific dosimetry. In:

Peter Ell, Sanjiv S. Gambhir, Eds. Nuclear Medicine in Clinical Diagnosis and Treatment,

Volume 1, 3rd Edition. Elsevier Science,375-382, 2004.

16. Sgouros G. Dosimetry of Internal Emitters. J Nucl Med 2005;46:18S-27S

17. Scheinberg DA, Mulford DA, Jurcic JG, Sgouros G, Junghans RP. Antibody therapies of

cancer. In: Chabner BA, Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles

and Practice, 4th Edition, Lippincott Williams and Wilkins, 667-698, 2006.

18. Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. MIRD continuing education:

Bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med

2007 Oct;48(10):1683-91.

19. Sofou S, Sgouros G. Antibody-targeted liposomes in cancer therapy and imaging. Expert

Opin Drug Deliv. 2008 Feb;5(2):189-204.

20. Sgouros G. Alpha particles for targeted therapy. Adv Drug Deliv Rev. 2008; 60(12):1402-6,

21. Sgouros G, Frey E, Wahl R, He B, Prideaux A, Hobbs R. Three-dimensional imaging-based

radiobiological dosimetry. Semin Nucl Med 2008; 38(5):321-34.

22. Sgouros G. Update: molecular radiotherapy: survey and current status. Cancer Biother

Radiopharm, 2008; 23(5):531-40.

23. Sgouros G. High-LET-Emitting Radionuclides for Cancer Therapy. In:Stigbrand T, Carlsson

J, Adams GP, Eds. Targeted Radionuclide Tumor Therapy, Biological Aspects, Springer

Sceince+Business Media B.V., 175-181, 2008.

24. Sgouros G. Radionuclides for Therapy. In: Pomper MG, Gelovani JG., Eds. Molecular

Imaging in Oncology, Informa Healthcare USA, 217-226, 2008.

25. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H,

Howell RW, Akabani G. MIRD Pamphlet No. 22 (abridged) - Radiobiology and dosimetry of

alpha-particle emitters for targeted radionuclide therapy. J Nucl Med, 2010 Feb;51(2):311-28.

Epub 2010 Jan 15

26. Song H, Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Curr

Drug Deliv. 2011 Jan 1;8(1):26-44.

GS 7/7/2017 19 sgourosCV_2017_07_07

27. Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Three-

dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid

cancer. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S41-7. Epub 2011 Apr 12

28. Sgouros G, Hobbs RF, Song H. Modelling and dosimetry for alpha-particle therapy. Curr

Radiopharm. 2011;4:261-5.

29. Meghzifene A, Sgouros G. IAEA support to medical physics in nuclear medicine. Semin Nucl

Med. 2013 May;43(3):181-7.

31. Sgouros G, Hobbs RF. Patient-Specific Dosimetry, Radiobiology, and the Previously-Treated

Patient. In: MEDICAL RADIOLOGY – Radiation Oncology, Edited by L.W. Brady, H.-P.

Heilmann, M. Molls, C. Nieder. Volume: Therapeutic Nuclear Medicine – Edited by Richard

P. Baum 2014

32. Sgouros G, Hobbs RF. Dosimetry for Radiopharmaceutical Therapy. Semin Nucl Med, 2014

May;44(3):172-8.

33. Brill AB, Sgouros G, Introduction. Sgouros G, Ed. MIRD Monograph- Radiobiology and

Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters Society of Nuclear

Medicine and Molecular Imaging Publishing, 2014

34. Brill AB, Fisher DR, Sgouros G, Historical Overview. Sgouros G, Ed. MIRD Monograph-

Radiobiology and Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters

Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

35. Allen BJ, Hobbs RF, Howell RW, Sgouros G, Song H. Alpha-Particle Radiobiology, Sgouros

G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with

Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

36. Hobbs RF, Howell RW, Sgouros G, Song H. Relative Biological Effectiveness. Sgouros G,

Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with

Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

37. Allen BJ, Hobbs RF, Roeske JC, Fisher DR, Sgouros G Alpha-Particle Dosimetry. Sgouros

G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with

Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

38. Allen BJ, McDevitt MR, Meredith RF, Palm S, Sgouros G, Torgue J, Zalutsky MR. Alpha-

Particle Emitters of Interest for Human Use. Sgouros G, Ed. MIRD Monograph- Radiobiology

and Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters Society of

Nuclear Medicine and Molecular Imaging Publishing, 2014

39. Howell RW, Sgouros G. Dosimetry Recommendations for Deterministic Effects. Sgouros G,

Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with

Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

GS 7/7/2017 20 sgourosCV_2017_07_07

40. Sgouros G. Summary. Sgouros G, Ed. MIRD Monograph- Radiobiology and Dosimetry for

Radiopharmaceutical Therapy with Alpha-Particle Emitters. Society of Nuclear Medicine and

Molecular Imaging Publishing, 2014

41. Fahey FH, Goodkind AB, Plyku D, Khamwan K, O’Reilly SE, Cao X, Frey EC, Li Y, Bolch

WE, Sgouros G, Treves ST. Dose Estimation in Pediatric Nuclear Medicine, Seminars in

Nuclear Medicine, Available online 9 November 2016, ISSN 0001-2998,

http://dx.doi.org/10.1053/j.semnuclmed.2016.10.006

C. Other

Conference Proceedings

1. Bigler RE, Sgouros G. Radiation Dosimetry of 15

O-labeled O2, CO

2, and CO gases

administered continuously in the breath. Nuclear Medicine and Biology, Vol II, p. 2000-2003,

C. Raynaud, Ed. Pergamon Press, New York, 1982.

2. Bigler RE, Zanzonico PB, Cosma M, Sgouros G. Adjuvant radioimmunotherapy for

micrometastases: A strategy for cancer cure. In Radiolabeled Antibodies for Imaging and

Therapy, NATO Advanced Study Institute, Barga, Italy, July 20 - August 1, 1986. Srivastava

SC (Ed), Plenum Press, New York, pp 409-429, 1988.

3. Zanzonico PB, Bigler RE, Sgouros G, Strauss A. Quantitative SPECT in radiation dosimetry.

Sem Nucl Med 19:47-61, 1989.

4. Zanzonico PB, Edwards C, Sgouros G, Strauss A, Bigler RE, Hurley JR, Becker DV. Practical

dosimetry: Quantitative imaging in radionuclide therapy. In: Dosimetry of Administered

Radionuclides. Eds: Adelstein SJ, Kasis AI, Burt RW. American College of Nuclear

Physicians and Society of Nuclear Medicine. Washington DC, 1989. p 275-294

5. Fisher DR, Sgouros G. Dosimetry of radium-223 and progeny. Proceedings of the 6th

International Radiopharmaceutical Dosimetry Symposium, May 7-10, 1996, Gatlinburg, TN;

Pgs. 375-391.

6. Behr TM, Sgouros G, Sharkey RM, Dunn RM, Blumenthal RD, Kolbert KS, Juweid ME,

Siegel JA, Goldenberg DM. 90Y-Dosimetry in the nude mouse: Evaluation of three dosimetry

models in relation to the observed biological effects in the radioimmunotherapy of human

colon cancer xenografts. Proceedings of the 6th International Radiopharmaceutical Dosimetry

Symposium, May 7-10, 1996, Gatlinburg, TN.

7. Sgouros G. Treatment planning for internal emitter therapy: Methods, applications and

clinical implications. Proceedings of the 6th International Radiopharmaceutical Dosimetry

Symposium, May 7-10, 1996, Gatlinburg, TN; pgs. 13-24.

8. Sgouros G. Alpha Particle Emitters in Cancer Therapy: Establishing the Rationale and

Overcoming the Difficulties. Proceedings of EPSMH '96, Engineering & the Physical

Sciences in Medicine & Health Conference, October 21-24, 1996, Canberra, Australia.

GS 7/7/2017 21 sgourosCV_2017_07_07

9. Sgouros G. Internal Emitter Dosimetry: Are Patient-Specific Calculations Necessary?

Proceedings of EPSMH '96, Engineering & the Physical Sciences in Medicine & Health

Conference, October 21-24, 1996, Canberra, Australia.

10. Sgouros G. Mathematical Models of Tumour Growth: Translating Absorbed Dose to Tumour

Control Probability Proceedings of EPSMH '96, Engineering & the Physical Sciences in

Medicine & Health Conference, October 21-24, 1996, Canberra, Australia.

11. Larson SM, El-Shirbiny AM, Divgi CR, Sgouros G, Finn RD, Tschmelitsch J, Picon A,

Whitlow M, Schlom J, Zhang J, Cohen AM. Single chain antigen binding protein (sFv CC

49): First human studies in colorectal cancer metastatic to liver. Cancer 1997;80(12

Suppl):2458-2468

12. Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert KS, Griffiths GL,

Siegel JA, Becker WS, Goldenberg DM. Overcoming nephrotoxicity of radiometal-labeled

immunoconjugates: Improved cancer therapy in a nude mouse model in relation to the internal

radiation dosimetry. Cancer 1997; 80(12 Suppl):2591-2610.

13. Sgouros G. Introduction to kidney dose-response for radionuclide therapy. Cancer Biother

Radiopharm 2004; 19:357 In: Sgouros, G. Wessels B., Guest Editors. Kidney Dose-Response

for Radionuclide Therapy. Cancer Biother Radiopharm 2004; 19:355-390.

14. Sgouros G, Hobbs RF, Abou DS. The role of preclinical models in radiopharmaceutical

therapy. Am Soc Clin Oncol Educ Book. 2014:e121-5. 10.14694/EdBook_AM.2014.34.e121

Editorial/Commentary

1. DeNardo GL, Maddock SW, Sgouros G, Scheibe PO, DeNardo SJ. Immunoadsorption: An

enhancement strategy for radioimmunotherapy. J Nucl Med 1993; 34:1020-1027.

2. Sgouros G. Radioimmunotherapy of micrometastases: Side-stepping the solid tumor hurdle. J

Nucl Med 1995; 36:1910-1912.

3. Zanzonico P, Sgouros G. Prediction of myelotoxicity in radioimmunotherapy: What does

dosimetry contribute? J Nucl Med 1997; 38:1753-1754.

4. Sgouros G. Long-lived Alpha Emitters in Radioimmunotherapy: The Mischievous Progeny.

Cancer Biother & Radiopharm 2000; 15:219-221.

5. Behr TM, Behe M, Jungclas H, Jungclas H, Becker W, Sgouros G. Higher relative biological

efficiency (RBE) of alpha-particles for acute effects: in vitro veritas, in vivo vanitas? Eur J

Nucl Med 2001; 28:1435-6.

6. Sgouros G. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer J Nucl

Med 2005; 46:899-900.

7. Sgouros G. Towards patient-friendly cell-level dosimetry. J Nucl Med 2007; 48:496-497.

GS 7/7/2017 22 sgourosCV_2017_07_07

8. Sgouros G. Molecular radiotherapy: Targeting cancer at the cellular level. MI Gateway,

Newsletter of the SNM Molecular Imaging Center of Excellence. J Nucl Med 2007, Dec issue.

9. Sgouros G. Update: molecular radiotherapy: survey and current status Cancer Biother

Radiopharm 2008; 23(5):531-540

10. Sgouros G, Howell RW, Bolch WE, Fisher DR. MIRD Commentary: Proposed Name for a

Dosimetry Unit Applicable to Deterministic Biological Effects--The Barendsen (Bd). J Nucl

Med 2009; 50(3):485-487.

11. Wessels BW, Dale RG, Cremonesi M, Meredith RF, Green AJ, Brill B, Bolch WE, Sgouros

G, Thomas SR. Renal Dosimetry. Cancer Biother Radiopharm. 2010 Oct;25(5):597-9.

12. Sgouros G, Goldenberg DM. Radiopharmaceutical therapy in the era of precision medicine,

Eur J Cancer. 2014 Sep;50(13):2360-3

13. Van Nostrand, D., Hobbs, R., Atkins, F.B. and Sgouros, G., 2016. 124I in Differentiated

Thyroid Cancer. In Thyroid Cancer (pp. 973-989). Springer New York

Media/interviews

http://www.cbsnews.com/news/a-new-frontier-in-the-war-on-cancer-4121081/

GS 7/7/2017 23 sgourosCV_2017_07_07

Patents and Software Copyrights

"Parametric image representation of imaging agent kinetics,"

Patent No.: 5684889, 11/4/1997.

"Alpha-Emitting Constructs & Uses Thereof,"

PCT application: PCT/US/99/11673

"Liposomal encapsulation of alpha-particle emitters and uses thereof,"

PCT Application: WO0197859

"Analysis and display software for multi-modality, longitudinal imaging studies: Multi-

modality Image Analysis Utility (MIAU),"

Copyright filed February 8, 2002

"Use of histone deacetylase inhibitors in combination with radiation for the treatment of

cancer,"

Provisional patent application: 60/373,033

Full List from Hopkins Tech transfer

TechId InternalId ApplicationType CountryName SerialNo FileDate PatentNo IssueDate InventorDept

InventorLastName: Sgouros

InventorFirstName: George

C04225

P04225-

02 PRO: Provisional United States 60/668,590 4/6/2005

Radiology

SOM

C04225

P04225-

01 PRO: Provisional United States 60/462,739 4/15/2003

Radiology

SOM

C04225

P04225-

03 PRO: Provisional United States 4/13/2004

Radiology

SOM

C04533

P04533-

01 PRO: Provisional United States 60/649,472 2/3/2005

Radiology

SOM

C04642

P04642-

01 PRO: Provisional United States 60/673,164 4/20/2005

Radiology

SOM

C05056

P05056-

03

PCT: Patent Cooperation

Treaty United States 12/514,853 9/15/2009

Radiology

SOM

C05056

P05056-

06 DIV: Divisional United States 15/132,590 4/19/2016

Radiology

SOM

C05056

P05056-

07 CON: Continuation United States

Radiology

SOM

C05056

P05056-

02

PCT: Patent Cooperation

Treaty PCT PCT/US2007/85400 11/21/2007

Radiology

SOM

C05056

P05056-

01 PRO: Provisional United States 60/860,315 11/21/2006

Radiology

SOM

C05056

P05056-

04 ORD: Ordinary Utility United States 12/687,670 1/14/2010 8,693,629 4/8/2014

Radiology

SOM

C05056

P05056-

05 CIP: Continuation-in-part United States 13/335,565 12/22/2011

Radiology

SOM

C05116

P05116-

01 PRO: Provisional United States 60/860,319 11/21/2006

Radiology

SOM

C05116

P05116-

02 PRO: Provisional United States 61/285,047 12/9/2009

Radiology

SOM

C10197

P10197-

01 PRO: Provisional United States 60/999,134 10/16/2007

Radiology

SOM

C10277

P10277-

03

PCT: Patent Cooperation

Treaty United States 12/811,620 3/14/2011

Radiology

SOM

C10277

P10277-

01 PRO: Provisional United States 61/009,779 1/2/2008

Radiology

SOM

GS 7/7/2017 24 sgourosCV_2017_07_07

C10277

P10277-

02

PCT: Patent Cooperation

Treaty PCT PCT/US2009/030039 1/2/2009

Radiology

SOM

C10810

P10810-

01 PRO: Provisional United States 61/228,241 7/24/2009

Radiology

SOM

C10810

P10810-

02 PRO: Provisional United States 61/296,667 1/20/2010

Radiology

SOM

C10968

P10968-

01 ORD: Ordinary Utility United States 12/690,471 1/20/2010 8,914,237 12/16/2014

Radiology

SOM

C12217

P12217-

03

PCT: Patent Cooperation

Treaty PCT PCT/US2013/066872 10/25/2013

WO

2014/066798 5/1/2014

Radiology

SOM

C12217

P12217-

01 PRO: Provisional United States 61/719,283 10/26/2012

Radiology

SOM

C12217

P12217-

02 ORD: Ordinary Utility United States

Radiology

SOM

C12217

P12217-

04

PCT: Patent Cooperation

Treaty United States 14/438,132 4/23/2015

Radiology

SOM

C12217

P12217-

05

PCT: Patent Cooperation

Treaty

European Patent

Office 13848483.7 10/25/2013

Radiology

SOM

C12230

P12230-

02

PCT: Patent Cooperation

Treaty PCT PCT/US2013/072147 11/27/2013

Radiology

SOM

C12230

P12230-

01 PRO: Provisional United States 61/731,170 11/29/2012

Radiology

SOM

C12230

P12230-

03

PCT: Patent Cooperation

Treaty United States 14/647,890 5/28/2015

Radiology

SOM

C13459

P13459-

01 PRO: Provisional United States 62/238,822 10/8/2015

Radiology

SOM

Research Support (PI or Co-PI)

Active

Title: R01CA187037 “Combined Biologic and Radiopharmaceutical Therapy of Breast Cancer” Time Commitment: .3 calendar months Supporting Agency:NIH/NCI – (Sgouros – PI) Performance Period: 05/01/2015 – 04/30/2020 Level of Funding( year 1): $477,660 Project Goal: Perform pre-clinical studies to make alpha-emitter radiopharmaceutical therapy, in combination with biological response modifiers an effective alternative to chemotherapy and pathway inhibition therapy in patients with metastatic cancer Specific Aims: 1. Identify αRPT/BRM combinations that lead to the greatest tumor cell kill, in vitro. 2. Assess pharmacokinetics, efficacy and toxicity of the αRPT/BRM combinations identified in Aim 1 for further study. 3. Develop a pharmarcokinetic/dosimetry model to fit response/toxicity data obtained in Aims 1 and 2. Title: R01CA116477 “Dose Response in Radionuclide Therapy” Time Commitment: .2.4 calendar months Supporting Agency:NIH/NCI – (Sgouros – PI) Performance Period: 5/1/2006 - 6/30/2017 Level of Funding: $228,963 Project Goal: The project goal is to develop and test dosimetry methodologies and software; applicable to radiopharmaceutical therapy Specific Aims: Collect dose-response studies, establish radiobiological reference human, implement micro to macro modeling Title: 1R01EB013558-01A1 Dose Reduction in Pediatric Molecular Imaging

GS 7/7/2017 25 sgourosCV_2017_07_07

Time Commitment: 2.4 Calendar months Supporting Agency: NIBIB (Sgouros, Frey –PI) Performance Period: 03/01/2012 – 03/31/2022 Level of Funding: $325,634 Project Goal: The objective of this proposal is to develop and validate techniques that can be used to reduce the radiation exposure to pediatric patients undergoing molecular imaging procedures using methods that retain the diagnostic quality of the images. Title: Modeling Targeted Alpha Particle Therapy of Cancer Time Commitment 1.2 calendar months Supporting Agency: NIH/NCI – (Hobbs) Performance Period 5/10/2012 - 4/30/2017 Level of Funding Agency: $54,201 Project Goal: Aim 1: Develop and test specific organ models for the organs most at risk from a-particle radioimmuniotherapy at the anatomical or functional sub-unit level. Aim: Adapt the idealized model to both measured murine and human parameters: aim 3: incorporate anatomical information from human cadavers to refine the human models for clinical use. Aim 4: Use therapeutic murine models to predict and control normal organ toxicity for in vivo model validation. Title: R01 CA109234 Quantitative SPECT for Targeted Radionuclide Therapy Time Commitment: .36 Calendar months Supporting Agency: NIH/NCI – (Frey – PI) Performance Period: 09/15/2011 - 07/3/2017 Level of Funding Agency: $247,497 Project Goal: The major goal of this grant is to develop iterative reconstruction technique for calculating cumulated activity, investigate advantages of longitudinal recon vs recon at each time-point Title: Comb. External Beam Radiotherapy with 153Sm-EDTMP to Treat High Risk Osteosarcoma Time Commitment: .6 Supporting Agency: NIH (Loeb-PI) Performance Period: 6/1/13 – 3/31/18 Level of Funding: $207,500 Project Goal: The goal of this study is to evaluate Comb. External Beam Radiotherapy with 153Sm-EDTMP to Treat High Risk Osteosarcoma

Title: JHU ICMIC Program Time Commitment .24 calendar months Supporting Agency: NIH/NCI – (Bhujwalla – PI) Performance Period 09/22/2011- 07/31/2016 Level of Funding Agency: $890,668 Project Goal: This center grant funds an In Vivo Cellular and Molecular Imaging Center at Johns Hopkins. The program consists of four research components, four developmental projects, one career development award and four resources Title: Regional Oncology Research Center Time Commitment: .12

GS 7/7/2017 26 sgourosCV_2017_07_07

Supporting Agency: NCI – Nelson PI Performance Period: 08/09/2012 – 04/30/2017 Level of Funding: $1,009,348 Project Goal: The aim of this grant: Consultation on proper choice and design of imaging studies in clinical trials. Aim 2: prompt and accurate assessment of tumor response. Aim 3: Image archival, anonymization and data import / export Title: R01CA184228 Small Molecule PSMA-Targeted Alpha Therapy Time Commitment: .6 Supporting Agency: NIH PIs: Pomper, Sgouros, Zalutsky Performance Period: 04/01/14 – 03/31/2019 Level of Funding: $412,893 Project Goals and Specific Aims: Major goals of TAT and this proposal are to show that the LMW agents we propose will enable high tumor penetration and limit toxicity to normal tissues Title: SPORE in Prostate Cancer Time Commitment: .6 Supporting Agency: NCI PI: Nelson Performance Period: 09/01/13 – 08/31/18 Level of Funding: $1,563,772 Project Goals and Specific Aims: Project #1 aims to introduce an entirely new imaging/therapy platform featuring the use of tumor-selective promoter driven transgenes;

GS 7/7/2017 27 sgourosCV_2017_07_07

Pending

Previous

5/1/92 - 4/30/93 Pilot-Mechanisms of Radiation Induced Activation of the Pentose

Phosphate Pathway in Rat Brain

NIH P01-CA29502 (sub-project)

PI (of P01): Richard Rivlin

Total direct costs:, $10,800

Role:PI of sub-project

10/1/92 - 9/30/96 Radioimmunotherapy of CML

NIH U01-CA58260

Total direct costs:

PI: David A. Scheinberg

Role: Leader, Modeling and Dosimetry

4/1/95 – 3/31/03 Modeling and Dosimetry for Radiolabeled Antibody Therapy

NIH R01-CA62444

Total direct costs: $2,319,458

Role: PI

6/14/95 - 6/14/97 Pharmacokinetics of Genetically Engineered Ab forms using PET

DOE 94-015

Total direct costs:

PI: Steven M. Larson

Role: Co-Inv

7/1/97 – 4/30/01 Antibody Therapy of Micrometastases

NIH R01 CA72683

Total direct costs: $674,253

Role: PI

1/1/00-12/31/04 Biological Approaches to the Treatment of Cancer; Biophysics/Nuclear

Medicine Core

NIH/NCI P01 CA33049

total direct costs: $686,500 (Core)

PI: Alan Houghton

Role: Co-PI of Core

3/1/00-3/1/03 NIH/NCI (P50) RFA CA-99-004

In Vivo Cellular and Molecular Imaging Centers (ICMICs); Imaging

Spheroid Growth and Vascularization, In Vivo

Total direct costs:

PI: Ronald Blasberg/Steven Larson

Role: PI of sub-project

11/1/00-10/31/03 Radiolabeled Herceptin to Increase Treatment Efficacy in Breast Cancer

Patients with Low Tumor HER2/neu Expression

GS 7/7/2017 28 sgourosCV_2017_07_07

Army Breast Cancer Research Program – Idea Award BC990927total

direct costs: $361,375

Role: PI

12/1/00-11/31/02 Targeted Delivery of Alpha Particle-Emitting Radionuclides and Their

Alpha-Emitting Progeny: Breast Cancer Therapy Using Liposome-

Encapsulated Alpha-Emitters Army Breast Cancer Research Program –

Concept Award BC996563

Total direct costs: $83,250

Role: PI

1/1/01-12/31/02 Combined Targeted Radionuclide Therapy and Chemotherapy of Prostate

Cancer CaP CURE Award

total direct costs:, $100,000

Role: PI

5/1/03 – 1/31/07 Advances in Skeletal Dosimetry Through Microimaging

NIH R01 CA096441

PI Wesley Bolch, U. Florida

total direct costs $52,656

Role: PI of sub-contract

9/30/03-10/31/06 Therapy of Ovarian Carcinoma by Targeted Delivery of Alpha-Particles

using Immunoliposomes Capable of Retaining Alpha-Emitting Daughters

DOD OCRP – IDEA Award DOD OC02009

total direct costs: $355,222

Role: PI

12/1/04-11/30/07 Patient-Specific Dosimetry and Radiobiological Modeling of Targeted

Radionuclide Therapy

Department of Energy, Office of Science (BER), - Grant No. DE-FG02-

05ER63967

total direct costs:$226,611 (funding terminated after 6 mos because DOE

program supporting grant was eliminated)

Role: PI

2/9/05-11/30/09 Targeted Alpha-Particle Therapy of Metastases

NIH/NCI R01 CA113797

total direct costs: $700,000

Role: PI

3/1/05-2/28/08 Combination Treatment of Her2/Neu Expressing Breast Cancer

Metastasis by Targeted Alpha-Particle Radioimmunotherapy And

Cancer Vaccine

DOD BCRP USARMC W81XWH05010290– Multidisciplinary

Fellowship

total direct costs $368,786

PI: Hong Song

GS 7/7/2017 29 sgourosCV_2017_07_07

Role: Mentor, 10 % effort (no salary)

7/1/06-6/30/07 Enhanced Anti-Tumor Immunization by Liposomal Delivery of Vaccine

to the Spleen

DOD BCRP –USAMRMC Concept Award BC052595

total direct costs: 75,000

Role: PI

7/1/06 – 6/30/09 Liposomal Delivery of High LET Emitters to Cell Nuclei

Ruth L. Kirstein National Research Service Award (NRSA)

1F32CA12365 -Fellowship in Nanotechnology for Medicine

total direct costs: $143,000

PI: Yah-el Har-el

Role: Mentor, 5% effort (no salary)

GS 7/7/2017 30 sgourosCV_2017_07_07

Clinical Trials

IRB00038617 Absorbed dose vs Response Database in Radiopharmaceutical Therapy

Acknowledged 5/29/2014 1:06 PM

Sgouros

IRB00067243 Phase 1 Biodistribution and Pharmacokinetic

Study of 11C-Rifampin PET in TB patients.

Approved 10/23/2015

4:57 PM

Jain

IRB00068376 Imaging of Viral Thymidine Kinase Activity in EBV-associated Nasopharyngeal Carcinoma

Withdrawn 5/6/2015 10:37 AM

Ambinder

NA_00005743 A Phase I/II Study of 131I-Tositumomab in Patients with Relapsed/Refractory Hodgkin’s Lymphoma

Expired 9/14/2013 8:13 PM

Wahl

NA_00019359 Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFBC PSMA based PET in Patients with Advanced Prostate Cancer

Expired 9/14/2013 10:51 PM

Cho

NA_00023048 F-18-FBnTP PET imaging in healthy subjects Approved 9/14/2013

9:38 PM

Madar

NA_00032681 Imaging of Viral Thymidine Kinase Activity in

EBV-Associated and KSHV-Associated Malignancies

Approved 9/14/2013

9:11 PM

Ambinder

NA_00052286 PET imaging of mitochondria function Approved 9/15/2013 12:02 AM

Madar

NA_00075773 Combination of External Beam Radiotherapy with 153Sm-EDTMP to Treat High Risk Osteosarcoma and Patients with Solid Tumors Metastatic to Bone

Approved 9/14/2013 2:05 PM

Loeb

NA_00077479 Validation of Dose Estimation Methods and Measurement of Normal Liver Dose in Y-90

Therasphere Therapy with Quantitative

Nuclear Imaging

Approved 9/14/2013 9:03 PM

Frey

NA_00092484 Phase 1 Biodistribution and Pharmacokinetic Study of 124I-DPA-713 translocator protein (TSPO) based PET in Normal Human Volunteers and Feasibility Study for Detection of Tuberculosis.

Approved 6/25/2014 3:00 PM

Jain

NA_00092956 Study of 18F-DCFPyL, a Second Generation low-molecular weight PSMA-based PET

radiotracer, in Patients with Prostate Cancer

Approved 5/16/2014 10:07 AM

Szabo

NA_00001712 Dose-Response in Radioimmunotherapy of Lymphoma

Expired 12/15/2008 2:56 AM

Sgouros

NA_00002264 Dose-Response in Radionuclide Therapy of Thyroid Cancer

Expired 12/15/2008 6:26 AM

Sgouros

NA_00015684

A Phase I/II, Multi- Center, Safety and Efficacy Study Evaluating Intravenously Administered 131- I- TM-601 in Patients with Progressive and/or recurrent Malignant Glioma

Withdrawn 4/6/2009 12:48 PM

Wahl

NA_00027502 Human Biodistribution and Dosimetry of Rubidium-82 Chloride

Approved 4/24/2009 12:42 PM

Wahl

GS 7/7/2017 31 sgourosCV_2017_07_07

NA_00050878 Absorbed dose vs Response Database in

Radiopharmaceutical Therapy Approved

7/22/2011

1:37 PM Sgouros

GS 7/7/2017 32 sgourosCV_2017_07_07

Teaching

Imaging Physics Lecture and Problem Course, MSKCC 1995-2003 – “Radionuclides for Nuclear

Medicine,” “Single-Photon Emission Computed Tomography (SPECT),”

Physics Lectures for Nuclear Medicine Residents and Fellows, MSKCC 1995-2003 –

“Introcution to Tracer Kinetic Modeling,” “Internal Radionuclide Radiation Dosimetry”

Lectures for Nuclear Medicine Residents and Fellows, Johns Hopkins University, School of

Medicine, Radiology 2003-2005 – “Internal Radionuclide Radiation Dosimetry,” “Introduction to

Radiobiology I and II”

“Modern Biomedical Imaging Instrumentation and Techniques” Johns Hopkins University

Engineering School course: ECE 520.434/ BME 580.472, Radiation Dosimetry/Radiobiology

lecture 2009-

"Modeling and Dosimetry of Radiolabeled Antibody Therapy" Seminar in Medical Physics,

Columbia University, Dept. of Applied Physics, New York NY, 1995

“Dosimetry and Treatment Planning for Radioimmunotherapy: Future Directions” Refresher

Course, Annual Meeting of the American Association of Physicists in Medicine, Boston, MA,

1995

"Radioimmunotherapy of Micrometastases: Alpha Particle Targeting of Multicellular Spheroids"

Columbia University, Seminar in Medical Physics, Dept. of Applied Physics, New York NY,

1998

"Dosimetry of Alpha Particles in Pre-Clinical and Clinical Studies"

Categorical Seminar, Speaker Annual Meeting, Society of Nuclear Medicine, St. Louis MO,

2000.

“Kidney Dose-Response for Radionuclide Therapy”

Continuing Education Session, Organizer/Moderator, Society of Nuclear Medicine

New Orleans, LO 2003

“Bystander and low-dose rate effects”

Continuing Education Session, Organizer/Moderator, Society of Nuclear medicine

San Diego, CA 2006

“Update on Dosimetry-Based Techniques in Thyroid Cancer”

CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy

Johns Hopkins University, Baltimore MD March 2008

“Targeted Therapy with Alpha-Particle Emitters - Dosimetry”

CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy

Johns Hopkins University, Baltimore MD March 2008

“Quantities and Units related to Deterministic Effects”

CME Course, Society of Nuclear Medicine, Annual Meeting

GS 7/7/2017 33 sgourosCV_2017_07_07

San Antonio, TX 2011

“Dosimetry, Radiobiology in Radiopharmaceutical Diagnosis and Therapy (i.e., nuclear

medicine)”

e-Radiology Physics Lecture Series,

Johns Hopkins University, Baltimore MD May 2012

“Future Directions for Individualized Pediatric Dosing Guidance”

MIRD CME Course, Society of Nuclear Medicine, Annual Meeting

Miami FL June 2012

“Quantifying Patient Risk in RIB Protocols and Clinical Trial Design”

MIRD CME Course, Society of Nuclear Medicine and Molecular Imaging, Annual Meeting

Miami FL June 2012

Radiobiology and Dosimetry of Alpha-Particle Emitter Therapy”

CME: Course, Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting,

St. Louis MO June 2014

ICMIC lecture, “Prospects for Combination Radiopharmaceutical Therapy”

Dept of Radiology, Johns Hopkins University, School of Medicine

Baltimore MD, September 2014

Johns Hopkins University, School of Medicine Translational Research Conference,

“Radioactive Pharmaceuticals that Target Cancer Cells-A Different Type of Targeted Biologic

Therapy”

Baltimore MD, October 2014

Mentoring

John D. Willins, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics

Co-advisor (w/ Clift Ling, Ph.D., MSKCC); ‘93–‘94, 1st prize Young Investigator, AAPM, 2000

Present position: Chief Medical Physicist, Dept. of Rad. Onc., Boston Medical Center, Boston,

MA

Eli E. Furhang, Columbia University Grad Student, Applied Physics

Co-Ph.D. Advisor (w/ Chen Chui, Ph.D., MSKCC); ‘95-‘97, Ph.D. awarded in ‘97

Present position: Physics Director, Beth-Israel Medical Center, New York, NY

Åse M. Ballangrud, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics

Advisor 6/97 – 8/00, received Army IDEA award in 2000

Present position: Associate Attending Physicist, Associate Member, Medical Physics, MSKCC,

New York, NY

Klaus A. Hamacher, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics

Advisor 12/97 – 5/01,

Present position: Medical Physicist, Columbia University, New York, NY

GS 7/7/2017 34 sgourosCV_2017_07_07

Stig Palm, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics

Advisor 3/01 – 3/03, 1st prize, Med Phys young investigator NY RAMPS, 2002

Present position:Prof. Dept. of Radiation Physics, Göteborg University, Sweden.

Richard Enmon, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics

Advisor 6/01 – 3/03,

Present position: Associate in the Intellectual Property Group, King & Spalder, New York.

Stavroula Sofou, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics

Advisor 10/01 – 3/03, Graduate Research Grant, Hellenic Univ. Club of New York

Present position: Assoc. Prof., Dept. of Chem. Engineering, Rutger’s University, New Jersey

Hong Song, Post-doctoral fellow, Johns Hopkins University, School of Medicine, Radiology

Awarded Multidisciplinary Post-Doctoral Fellowship Award from Department of Defense Breast

Cancer Research Program (BCRP). Titled: “Combination Treatment of HER2/neu Expressing

Breast Cancer Metastasis by Targeted alpha-Particle Radioimmunotherapy and Cancer Vaccine”.

Promoted to Research Associate in 2008

Received an exploratory grant award, “Targeting metastatic pancreatic cancer stem cells by alpha

particle radiation” from the Maryland Stem Cell Research Fund in 2009, 7/1/2009-6/30/2011,

207k direct.

Assist Prof., Dept of Radiology, Johns Hopkins University, School of Medicine

Advisor 12/03 – 6/09

Present position: Medical Fellow in Nuclear Medicine, Stanford University

Yah-el Har-el, Post-doctoral fellow, Johns Hopkins University, School of Medicine, Radiology

Awarded the Ruth L. Kirstein National Service Award Fellowship (NIH), Project title:

“Liposomal Delivery of High LET Emitters to Cell Nuclei”

Advisor 6/05 – 12/09

Present position: Assistant Professor, Bioengineering, Temple University, College of

Engineering

Andrew Prideaux, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology

Advisor 5/05 –6/08

Present position: Clinical Applications Specialist, Hermes Medical Solutions, Stockholm,

Sweden

Mohanambe Lingappa, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology

Awarded the Multidisciplinary Post-Doctoral Fellowship Award from the Department of Defense

Breast Cancer Research Program (BCRP), Project title: “Anti-tumor immunization by liposomal

delivery of vaccine to the spleen”

Advisor 4/06 –2010

Robert Hobbs, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology

Advisor 5/06 –2012, received NIH R01 grant, “Modeling Targeted Alpha Particle Therapy of

Cancer” in 2012.

Present position: Asssistant Professor, Johns Hopkins University, SOM, Radiation Oncology

GS 7/7/2017 35 sgourosCV_2017_07_07

Sebastien Baechler, Visiting fellow, University Institute of Radiation Physics, Lausanne

University, Lausanne, Switzerland. Recipient of a Swiss National Science Foundation:

fellowship No. PBFR2-115886.

Advisor 3/07-3/08

Wietske van der Weg, Visiting fellow, Department of Nuclear Medicine, Radboud University

Nijmegen Medical Centre, Nijmegen, The Netherlands.

Advisor 9/11-11/11

Senthamizhchelvan Srinivasan, Post-doctoral fellow, Johns Hopkins University, SOM,

Radiology, Recipient first place, Young Investigator Award, Society of Nuclear Medicine and

Molecular Imaging.

Advisor 10/08 –7/12

Donika Plyku, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology

Advisor 8/12 –

Sagar Ranka, Visiting Medical Student, Lokmanya Tilak Municipal Medical College, India

Research Elective Mentor 4//14 – 6/14

Post-doctoral fellow 9//15 – 4/16

Present position: Medical Fellow Rush Medical School, Chicago IL

Anders Josefsson, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology,

Advisor 1/14-

Fabien Jammes, intern, 7/14-9/14

Kitiwat Khamwan, Ph.D., Post-doctoral fellow, Johns Hopkins University, SOM, Radiology,

Recipient first place, Young Investigator Award, Society of Nuclear Medicine and Molecular

Imaging

Advisor 1/15-10/15

Ian Beh, Visiting Medical Student, Cambridge University College of Medicine, Cambridge UK

Research Elective Mentor 6/15 – 8/14

Ahmed Noor, Visiting Medical Student, Windsor University School of Medicine, Research

Elective Mentor, 1/15-3/15.

Valentina Ferri Ph.D. physics trainee, University of Bologna, Santa Maria Nuova Hospital in

Reggio Emilia, Italy 9/15-10/15.

Ahmed Noor, MD Volunteer, 9/15-12/15

Ivan Guan – Bioengineering undergrad,

Aneesh Patankar – Bioengineering undergrad

Nader Moshiri, Ph.D. candidate, Florida Atlantic University

GS 7/7/2017 36 sgourosCV_2017_07_07

Ph.D. Thesis committees

Kristina Norrgren, “Radiolabeled Monocolonal Antibodies, Development of a New Method to

Remove Circulating Activity – Diagnostic Applications and Implications for Therapy,” Guest

opponent, oral defense, Lund, Sweden, 1993.

Eli Furhang, “A Monte Carlo-Based Dosimetry Method For Patient-Specific Internal Emitter

Therapy” Columbia University Grad Student, Applied Physics

Co-Ph.D. Advisor (w/ Chen Chui, Ph.D., MSKCC); ‘95-‘97

Peter S. Kim, “Characterization of the Biophysical, Molecular, and Immunological

Consequences of Antibody-Tumor Interaction on the Development of Potent Antitumor

Immunity,” Johns Hopkins University, School of Medicine, Department of Pharmacology and

Molecular Sciences

Thesis Advisory Committee Member 2005-2007

Bin He, Medical Imaging Physics Division, Department of Radiology

Examining Committee Member, 2005-2006, Ph.D

Chris Watchman, “Alpha Particle Dosimetry: 3D Image based Models of Normal Bone for use in

Radionuclide Therapy,” University of Florida, Department of Nuclear and Radiological

Engineering.

Thesis Advisory Committee Member 2003-2005

Andrew L. DuFresne Johns Hopkins University, School of Medicine, Biochemistry, Cellular, and

Molecular Biology Program

Thesis Advisory Committee Member 2008-

Thomas Bäck, University of Gothenburg, Invited Opponent, Ph.D. Thesis Defense, May 2011

Michael Wayson “Computational internal dosimetry methods as applied to the University of

Florida series of hybrid phantoms” University of Florida, J. Crayton Pruitt Family Department of

Biomedical Engineering. Examining Committee Member 2011-2012.

Lishui Cheng “Development and characterization of convergent and fast penalized SPECT image

reconstruction methods for targeted radionuclide therapy dosimetry”

Thesis Advisory Committee Member 2011-2013

Xing Rong “Development and evaluation of quantitative Y-90 bremsstrahlung SPECT methods”

Thesis Advisory Committee Member 2011-2013

Nate Crookson Chair, advancement to candidacy exam Electrical and computer science

engineering, Hopkins, October 2016

Editorial Activities

GS 7/7/2017 37 sgourosCV_2017_07_07

Reviewer: Cancer Biotherapy and Radiopharmaceuticals, Cancer Research, Clinical Cancer

Research, International Journal of Cancer, Journal of Nuclear Medicine, Medical Physics,

Physics in Medicine and Biology, International Journal of Radiation Biology, PLoS

Guest Editor: Medical Physics, Journal of Nuclear Medicine

Editorial Board Member: Cancer Biotherapy and Radiopharmaceuticals

Scientific and Medical Societies

Society of Nuclear Medicine

American Association of Physicists in Medicine

American Association for Cancer Research

American Association for the Advancement of Science

Committees/Review Panels

Steering Committee Member (1995-2000),

American Association of Physicists in Medicine (AAPM),

Task Group on Internal Emitter Dosimetry

Chairman (1996), Dosimetry, Physics and Radiobiology Panel,

Department of Energy,

Alpha-Emitters for Medical Therapy Workshop

Chairman (1997-2003), Sub-Committee on Non-Human Use,

Committee on Radiation,

Memorial Sloan-Kettering Cancer Center

Study Section Member ('97, '98),

Biomedical Research Technology Special Emphasis Panel

National Center for Research Resources, National Institutes of Health

NCI Study Section Site Visit, City of Hope National Medical Center (’99)

Study Section member, Advanced Nuclear Medicine Initiative, Dept. of Energy ('00)

Member (2000 - ), Vice Chairman (2006 - 2008), Chairman (2008 - )

Medical Internal Radiation Dose (MIRD) Committee,

Society of Nuclear Medicine

Oncological Sciences IRG Study Section Boundaries Team member (2001),

NIH, Center for Scientific Review

"develop recommendations for … study sections that will be responsible for

reviewing grant applications in the oncological sciences"

Member, National Council on Radiation Protection and Measurements (NCRP), Scientific

Committee 6-3, Uncertainties in Internal Radiation Dosimetry (2005-2010)

Member, Board of Directors, Molecular Imaging, Center of Excellence,

Society of Nuclear Medicine (2007)

DOD Breast Cancer Research Program (2007, 2008)

Member, Breast Cancer Review Training Panel

GS 7/7/2017 38 sgourosCV_2017_07_07

Study Section Member (2008)

NIH, National Institute of Allergy and Infectious Diseases, Special Emphasis Panel

Mechanisms, Diagnosis, and Treatment of Radiation Injury

from Nuclear Accident or Terrorist Attack

Organizing Committee Member (2009)

International Atomic Energy Association (IAEA), International Symposium on Standards,

Applications and Quality Assurance in Medical Radiation Dosimetry, Vienna Austria

Chair, Organizing Committee (2008-2009), International Symposium on Radionuclide

Therapy and Radiopharmaceutical Dosimetry (ISRTRD), Toronto, Canada

DOD Breast Cancer Research Program (2010)

Member, Breast Cancer Review Training Panel

Study Section Member (2010)

NIH, NIBIB, Special Emphasis Panel

Training/Career Opportunity Awards

Member (2010-), Scientific Advisory Board, AREVA Med, LLC

Ad Hoc Reviewer (2011),

Transplantation, Tolerance and Tumor Immunology (TTT) Study Section NIH

Scientific Advisor (2012- )

Metrology for Molecular Radiotherapy (MetroMRT) grant from the European Metrology

Research Programme, Joint Research Proposal

Standing Study Section Member (2012-2017)

NIH, Radiation Therapeutics and Biology (RTB)

Council Member, (2013-)

National Council on Radiological Protection and Measurements (NCRP)

Member, Scientific Committee of the IAEA/WHO Network of Secondary Standards

Dosimetry Laboratories, (2014-)

Member, The International Commission on Radiation Units and Measurements (ICRU),

Report Committee on “Bioeffect Modeling and Equieffective Dose Concepts in Radiation

Therapy” (2014-)

Chairman, Radiation Therapeutics and Biology (RTB) study section (2015-2017)

Chairman, The International Commission on Radiation Units and Measurements (ICRU),

Report Committee on “Treatment Planning for Radiopharmaceutical Therapy” (2016-)

Honors & Awards

New York State Regents Scholarship 1980 - 1984

Dean's Honor Roll, Columbia University 1980 - 1984

National Physics Honor Society 1983

National Engineering Honor Society 1983

GS 7/7/2017 39 sgourosCV_2017_07_07

Departmental nomination for 1984

George Vincent Wendell Award

Columbia University, Applied Physics Dept.

Cancer Research Institute/Jesselson Foundation Fellowship 1991

First Prize, American Association of Physicists in Medicine, 1993

Young Investigator Award - John Willins Awardee

George Sgouros - senior author and supervisor.

Louise and Allston Boyer Young Investigator Award, 1998

Memorial Sloan-Kettering Cancer Center,

CaP CURE Award 2001

SNMMI Saul Hertz Award 2017

for outstanding achievements and contributions in radionuclide therapy

Invited Talks, Panels

"Radiation Effects on Brain Glucose Metabolism: Potential for Early Prediction of Damage using

PET and MRS," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New

York, 1989.

"Conformal Treatment Planning for Radioimmunotherapy" Nuclear Medicine Seminar,

Memorial Sloan-Kettering Cancer Center, New York, 1992

"Conformal Treatment Planning for Radioimmunotherapy" Center for Molecular Medicine and

Immunology, Garden State Cancer Center, Newark, New Jersey, 1993

"Physicists Role in Clinical Radioimmunodiagnosis and Therapy" Scientific Symposium,

Annual Meeting of the American Association of Physicists in Medicine, Washington, D.C., 1993

"The Role of Modeling and Dosimetry in Achieving Success with Radioimmunotherapy"

Nuclear Medicine Seminar,

Memorial Sloan-Kettering Cancer Center, New York, 1993

“Modeling and Dosimetry for Radiolabeled Antibody Therapy” Rheumatology Grand Rounds,

Hospital for Special Surgery, New York, 1994

"Modeling and Dosimetry of Radiolabeled Antibodies: Identifying the Optimal Parameters for

Radioimmunotherapy"

Brookhaven National Laboratory, Upton, New York 1995

"Treatment Planning for Internal Emitter Therapy: Methods, Applications, and Clinical

Implications" Invited Paper, 6th International Radiopharmaceutical Dosimetry Symposium,

Gatlinburg TN 1996

"Alpha Particle Emitters in Cancer Therapy: Establishing the Rationale and Overcoming the

Difficulties," "Internal Emitter Dosimetry: Are Patient-Specific Calculations Necessary?"

GS 7/7/2017 40 sgourosCV_2017_07_07

"Mathematical Models of Tumour Growth: Translating Absorbed Dose to Tumour Control

Probability"

Keynote Speaker, Engineering & Physical Sciences in Medicine & Health Conference, Canberra,

Australia, 1996

"Patient-Specific Dosimetry," invited presentation, International Research Group in

Immunoscintigraphy and Immunotherapy,

Barcelona, Spain, May 1998.

"Patient-Specific Dosimetry," invited presentation, International Research Group in

Immunoscintigraphy and Immunotherapy,

Göttingen, Germany, May 1999.

"Spheriod Studies with Alpha-Emitter Labeled Antibodies"

Nuclear Medicine Seminar,

Memorial Sloan-Kettering Cancer Center, New York, 2000.

"Preliminary Experience with Three-Dimensional Dose Assessment and Treatment Planning"

Continuing Education session, Annual Meeting, Society of Nuclear Medicine, St. Louis MO,

2000.

"Dosimetry for Antibody and Peptide based Radionuclide Therapy"

Nuklearmedizinische Klinik und Poliklinik,

Technische Universität Munchen, 2000.

"Patient Dosimetry for 213Bi-HuM195"

Medical Internal Radionuclide Dose (MIRD) Committee meeting

Delray Beach, FL, 2000

“Clinical Dosimetry Studies”

Invited Presentation, 7th International Radiopharmaceutical Dosimetry Symposium

Nashville TN 2002

“Radionuclide Therapy and Dosimetry”

Invited Presentation, European Association of Nuclear Medicine Annual Congress

Vienna, Austria 2002

"Alpha-Particle Emitter (225Ac)-labeled Herceptin Antibody Targeting of Breast Cancer: Efficacy

Vs. HER-2/neu Expression"

Invited Presentation, Era of Hope, DoD Breast Cancer Research Program Meeting

Orlando, FL, 2002

“The Radiation Physics of Targeted Therapy”

Educational Symposium, Society of Nuclear Medicine mid-winter meeting

Anaheim, CA. 2004

“Predicting Response and Toxicity: The Role of Dosimetry”

2nd International Workshop on Nuclear Oncology

Aventura, FL. 2004

GS 7/7/2017 41 sgourosCV_2017_07_07

“Innovations in Tumor Dosimetry – Implications for Radioisotope Therapy Treatment Planning”

Categorical Seminar, Society of Nuclear Medicine

Philadelphia, PA. 2004

Panel Discussion: “The Future of Radioimmunotherapy,” Panel Member, 10th Conference on

Cancer Therapy with Antibodies and Immunoconjugates,

Princeton NJ, 2004

“Trends in Dosimetry for Therapy,”

Translational Applications of Molecular Imaging and Radionuclide Therapy

Toronto, Canada. 2005

"Pre-Clincial Model for Targeted Alpha-Emitter Therapy of Early Breast Cancer Metastases,"

Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center,

New York NY 2005

"Radioimmunotherapy and Lack of Dosimetry and Standards,"

14th Annual Meeting Council on Ionizing Radiation and Measurement Standards

Gaithersburg MD 2005

"Skeletal Dosimetry at Johns Hopkins University," Mini-Symposium on Skeletal Dosimetry

Advanced Laboratory for Radiation Dosimetry Studies, Dept. of Nuclear and Radiological

Engineering, University of Florida,

Gainesville FL 2005

“Dosimetry for Radionuclide Therapy,”

Fudan University Hospital,

Shanghai, China 2005

"New Dosimetric Methods: Voxel-based Dosimetry"

European Association of Nuclear Medicine, Annual Meeting; 2nd International Symposium on

Radionuclide Therapy and Radiopharmaceutical Dosimetry

Athens, Greece 2006

"Radiation Biology and Individual Patient Dosimetry in Therapeutic Nuclear Oncology"

World Congress of Nuclear Medicine and Biology

Seoul, S. Korea 2006

“Modeling and Dosimetry for Targeted Radionuclide Therapy”

MD Anderson Cancer Center

Department of Experimental Diagnostic Imaging

Houston TX 2007

“Radioimmunotherapy and Targeted Alpha-Particle Therapy”

The Baltimore-Washington Chapter of the Health Physics Society

and The Mid-Atlantic Chapter of the American Association of Physicists in Medicine

Columbia, MD 2007

GS 7/7/2017 42 sgourosCV_2017_07_07

“Regional (AFRA) training course on medical internal dosimetry relevant to nuclear medicine.”

International Atomic Energy Agency

Technical Cooperation Project

RAF/6/032: Promoting Regional and National Quality Assurance Programmes for

Medical Physics in Nuclear Medicine (AFRA II-7)

Tunis, Tunisia, N. Africa Nov. 2007

“Update on Dosimetry-Based Techniques in Thyroid Cancer”

CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy

Johns Hopkins University, Baltimore MD March 2008

“Targeted Therapy with Alpha-Particle Emitters - Dosimetry”

CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy

Johns Hopkins University, Baltimore MD March 2008

“Antibody-Targeted Liposomes in Cancer Therapy and Imaging”

Pfizer, Inc. Cambridge MA April 2008

“The Emerging Role of Radiotherapeutics in Oncology”

Grand Rounds, FDA, Silver Spring MD April 2008

“Radionuclide Therapy and Dosimetry in Nuclear Medicine”

Scientific Symposium, Annual Meeting of the American Association of Physicists in Medicine,

Houston, TX, July 2008

“Dosimetry for Radionuclide Therapy”

Oncology Research Institute (ORI)/NUMI & Cancer Research Centre of Excellence,

National University of Singapore,

Singapore Novemeber 2008

“Radionuclide Dosimetry and Targeted Alpha-Emitter Therapy”

Grand Rounds, Department of Radiation Oncology and Molecular Radiotherapeutics, Johns

Hopkins University, School of Medicine,

Baltimore MD, March 2009.

“Immunoliposomes for Targeted Radionuclide Therapy”

Scientific Symposium, Annual Meeting of the American Association of Physicists in Medicine,

Anaheim, CA, July 2009

“Targeted Alpha-Particle Emitter Therapy of Metastatic Breast Cancer”

Translational Research Conference, Johns Hopkins University, School of Medicine,

Baltimore MD, October 2009

“Targeted alpha-emitter therapy and Patient-Specific 3D-Radiobiological Dosimetry (3D-RD)"

Radiation Epidemiology Branch, NIH NCI

Bethesda MD, October 2009

GS 7/7/2017 43 sgourosCV_2017_07_07

“3D-RD Patient-Specific Dosimetry for Thyroid Cancer”

Washington Hospital Center,

Washington DC, December 2009

“Introduction: Internal Dosimetry for Radionuclides,”

Joint International Center for Theoretical Physics-International Atomic Energy Association

Advanced School on Internal Dosimetry

Trieste, Italy, April 2010

“3D-RD Imaging-Based Dosimetry,”

Joint International Center for Theoretical Physics-International Atomic Energy Association

Advanced School on Internal Dosimetry

Trieste, Italy, April 2010

“Bexxar Dosimetry,”

Joint International Center for Theoretical Physics-International Atomic Energy Association

Advanced School on Internal Dosimetry

Trieste, Italy, April 2010

“2009 MIRD Committee Recommendations for Unifying MIRD and ICRP Formulas,

Quantities, and Units,”

Joint International Center for Theoretical Physics-International Atomic Energy Association

Advanced School on Internal Dosimetry

Trieste, Italy, April 2010

“PET Quantification,”

Joint International Center for Theoretical Physics-International Atomic Energy Association

Advanced School on Internal Dosimetry

Trieste, Italy, April 2010

“Dosimetry for Targeted Radionuclide Therapy,”

Workshop: Functional Imaging for Radiotherapy

Vancouver, Canada, April 2010

“Modeling and Dosimetry for Targeted Radionuclide Therapy”

SCK-CEN, Belgian Nuclear Research Centre

Mol, Belgium, July 2010

“Modeling and Dosimetry for Targeted Radionuclide Therapy”

Munich Technical University

Munich, Germany, July 2010

“Patient-Specific Dosimetry and Targeted alpha-emitter therapy”

Brigham and Women’s Hospital, Dana Farber Cancer Institute

Boston MA October, 2010

Keynote lecture, “Alpha-Particle Emitter Therapy: Radiobiology and Dosimetry”

Targeted Alpha-Radionuclides to Combat Cancer (TARCC) Consortium Congress,

Ljubljana, Slovenia, November 2010

GS 7/7/2017 44 sgourosCV_2017_07_07

Keynote lecture, “Dosimetry in Radiopharmaceutical Therapy”

Swiss Society of Radiobiology and Medical Physics, Annual Meeting

Bern, Switzerland, November 2010

“Dosimetry for Radiopharmaceutical Therapy: Past, Present and Future”

CME Course, Society of Nuclear Medicine, Mid-Winter Meeting

Palm Springs CA, January 2011

“Dosimetry for Radiopharmaceutical Therapy”

Division of Medical Imaging Physics, Dept. of Radiology

Johns Hopkins University, SOM,

Baltimore MD, March 2011

“Targeted Alpha-Particle Emitter Therapy of Breast Cancer: Sidestepping some of the Biological

Obstacles to Treatment Efficacy”

Breast Cancer Novel Therapeutics/Correlative Sciences Working Group, Med Onc

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital

Baltimore MD May 2011

“Alpha-Particle Emitter Therapy: A New and Promising Cancer Therapy”

Invited Opponent, Ph.D. defense of Thomas Bäck

Gothenburg University

Gothenburg, Sweden May 2011

“Quantities and Units related to Deterministic Effects”

CME Course, Society of Nuclear Medicine, Annual Meeting

San Antonio, Texas, June 2011

“Alpha-Particle Emitter Dosimetry: The Fallible Mean”

7th Symposium on Targeted Alpha Therapy,

Berlin, Germany July 2011

IAEA Consultant’s meeting on internal dosimetry

Vienna, Austria September 2011

“Dosimetry in Radiopharmaceutical Diagnosis and Therapy”

FDA Visiting Professor Lecture

Silver Spring MD, December 2011

“Evolution in Modeling and Dosimetry of Radioimmunotherapy”

World Radioimmunoconjugate Summit

Washington DC, January 2012

“I-124 PET/CT in Patient-Specific Thyroid Dosimetry for Treatment Planning”

21st Interdisciplinary Medical Symposium, 251st Air Force General Hospital

Athens, Greece, February 2012

GS 7/7/2017 45 sgourosCV_2017_07_07

IAEA Consultant’s meeting on IAEA contributions to Nuclear Medicine Physics

Vienna, Austria June 2012

“Individualized Pediatric Dosing Guidance”

Royal Marsden Hospital and Institute of Cancer Research,

Sutton, UK June 2012

Scientific Advisor,

European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy

London, UK June 2012

“How to Improve Dosimetry for Radiopharmaceutical Therapy,”

“Alpha-Emitters in Nuclear Medicine Therapy: Overview”

Annual Congress of the European Association of Nuclear Medicine

Milan, Italy October 2012

Scientific Advisor,

European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy

Delft, Netherlands December 2012

“Radiopharmaceutical Dosimetry Workshop”

“Treatment Planning and Dosimetry for Alpha-Emitters”

World Radioimmunoconjugate Summit

Washington DC, February 2013

“Treatment Planning for Alpha-Emitter Therapy”

2nd World Congress on Ga-68, Molecula Imaging, Targeted Radionuclide Therapy and

Dosimetry

Chandigarh, India, March 2013

“Targeted Alpha-Emitter Therapy of Breast Cancer:

Pathways to a Phase I trial”

Breast Cancer Novel Therapeutics/Correlative Sciences Working Group, Med Onc

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital

Baltimore MD March 2013

“Physics of Radionuclide Therapy”

NCI/SNMMI joint workshop on Targeted Radionuclide Therapy

National Institutes of Health Campus

Bethesda MD March 2013

“Matching the Method with the End-Point: Dosimetry for Radiopharmaceutical Therapy”

Cancéropôle International Young Investigators Workshop: Radiobiology Applied to Oncology

Domaine de Ramonjuan – Vallée de Lesponne

France April 2013

“Radiobiology and Mechanism of Action of Radium-223”

prIME Oncology Symposium, SNMMI Annual Meeting

GS 7/7/2017 46 sgourosCV_2017_07_07

Vancouver BC,

Canada June 2013

“Dosimetry and Radiobiology of alpha-Particle Emitters”

IAEA Technical Meeting on:

Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy

Vienna, Austria June 2013

Scientific Advisor,

European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy

Rome, Italy July 2013

“Treatment Planning for Alpha-Emitter Radiopharmaceutical Therapy”

Workshop on Innovative Personalized Radioimmunotherapy

Nantes, France July 2013

IAEA Expert Mission, “National Meeting and Workshop on Qualification and Diffusion of

Quantitative Emission Tomography (PET/CT and SPECT/CT)”

Sao Paulo, Brazil Dec, 2013

IAEA 16th Biennial Meeting of the SSDL Scientific Committee for the Evaluation of and

Recommendations on the Dosimetry Programme and the IAEA/WHO SSDL Network,

Vienna, Austria March 2014

European Society for Therapeutic Radiology and Oncology (ESTRO), 33rd Annual Meeting,

“Dosimetry: The worlds of radionuclides and external beams - incongruent and incompatible?”

Vienna, Austria April 2014

American Society of Clinical Oncology (ASCO), 50th Annual Meeting,

Chair, Radiopharmaceuticals: Spanning Hematologic Malignancies to Solid Tumors

Speaker: Preclinical models of radioimmunotherapy/antibody conjugates: Translation to the

clinic

Chicago, IL May 2014

Scientific Advisor,

European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy

Paris, France May 2014

Radiology Translational Research Seminars, Rapid Fire Presentation – Research in Nuclear

Medicine – Radiopharmaceutical Therapy and Dosimetry Lab”

Johns Hopkins University, SOM, Dept of Radiology, May 2014

Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting,

CME:“Radiobiology and Dosimetry of Alpha-Particle Emitter Therapy”

St. Louis MO June 2014

Biennial Prostate Cancer UK Forum, “Radiopharmaceutical Therapy”

Baltimore MD, June 2014

GS 7/7/2017 47 sgourosCV_2017_07_07

Winthrop Rockefeller Cancer Institute Forum

“Radioactive Pharmaceuticals that Target Cancer Cells-A Different Type of Targeted Biologic

Therapy”

Little Rock AK, September 2014

ICMIC lecture, “Prospects for Combination Radiopharmaceutical Therapy”

Dept of Radiology, Johns Hopkins University, School of Medicine

Baltimore MD, September 2014

Johns Hopkins University, School of Medicine Translational Research Conference,

“Radioactive Pharmaceuticals that Target Cancer Cells-A Different Type of Targeted Biologic

Therapy”

Baltimore MD, October 2014

Scientific Advisor,

European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy

Prague, Czech Republic December 2014

Johns Hopkins University, School of Medicine Sarcoma Work in Progress Conference

“Radioapharmaceutical therapy of Osteosarcoma”

Baltimore MD, January 2015

Scientific Advisor,

European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy

Thessaloniki, Greece, May 2015

Theagenion Hospital Cancer Center,

Patient-Specific 3D Dosimetry in Molecular Radiotherapy

Thessaloniki Greece, May 2015

9th Symposium on Targeted Alpha Therapy

Moderator, Dosimetry and Instrumentation Session

Warsaw, Poland, May 2015

Genentech/Roche Scientific Advisory Board meeting on alpha-particle therapy/dosimetry

“Radiopharmaceutical Therapy and Treatment Planning in the Era of Precision Medicine”

Basel, Switzerland, July 2015

Bayer HealthCare, Alpha Particle Dosimetry Seminar

“Dosimetry and Radiobiology for Alpha-Emitter Therapy: Transitioning from Cells and Mice to

Humans”

Berlin, Germany September 2015

Chairman and speaker,

IAEA Consultants Meeting

“Dosimetry and Radiobiology for Alpha-Particle Emitter Therapy”

Vienna, Austria, November 2015

GS 7/7/2017 48 sgourosCV_2017_07_07

University of Saskatoon, Symposium on Radiotherapeutics

“Radiopharmaceutical therapy with beta and alpha-particle emitters in the Era of Precision

Medicine”

Saskatoon, Saskatchewan, Canada October 2015

Columbia University, Visiting Professor Lecture

“Treatment Planning for Radiopharmaceutical Therapy” (invited lecture)

“Dosimetry for Radiopharmaceutical Therapy vs Diagnosis” (fellows lecture)

New York NY, January 2016

Washington University in St Louis, School of Medicine, Visiting Professor Lecture

“Treatment Planning for Radiopharmaceutical Therapy”

St Louis MO, January 2016

Florida Atlantic University, Visiting Professor Lecture

“Dosimetry and Radiobiology for Alpha-Particle Emitter Therapy”

Boca Raton FL, February 2016

Johns Hopkins University, SOM, Radiation Oncology Retreat, keynote speaker

“Radiopharmaceutical Therapy in the era of Precision Medicine”

Baltimore MD, February 2016

IAEA 17th Biennial Meeting of the Secondary Standards Dosimetry Lab (SSDL) Scientific

Committee for the Evaluation of and Recommendations on the Dosimetry Programme and the

IAEA/WHO SSDL Network,

Vienna, Austria March 2016

Memorial Sloan-Kettering Cancer Center Keynote Lecture, “Modern Radiation Dosimetry for

Targeted Radiotherapy,” Imaging and Radiation Sciences (IMRAS) Research Symposium,

New York NY May 2016

Johns Hopkins University, School of Medicine Fellows Research Conference,

“Radiopharmaceutical Therapy in the Era of Precision Medicine”

Baltimore MD, September 2016

FDA, Invited presentation on internal dosimetry,

“Dosimetry for Radiopharmaceutical Therapy”

Silver Spring MD, October 2016

Radiation Research Society, Continuing Medical Education Session

“Radiopharmaceutical Therapy in the Era of Precision Medicine”

Big Island HA, October 2016